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ABSTRACT 
 
 
A COMPARISON OF EXCESS FLUID TO BE REMOVED IN HAEMODIALYSIS 
PATIENTS, AS ESTIMATED BY HD STAFF VERSUS MULTIPLE FREQUENCY BIA. 
Downs Jane H1,2, Veldman FJ2, Kassier S2  
King Edward VIII Hospital (KEH)1, & UKZN2 
jane.downs3@gmail.com 
 
Background: Currently, in most haemodialysis (HD) units in South Africa, the excess 
fluid to be removed in HD, is estimated by comparing the previous post-HD versus the 
subsequent pre-HD body weight (wt). Bioelectrical impedance analysis (BIA) may 
potentially yield more accurate estimates that protect the HD patients from the risks 
associated with under and over-hydration.  
Objective: To compare excess fluid to be removed in HD as estimated by the staff and 
multiple frequency BIA.  
Methods: A prospective, non-randomized observational study was conducted. 
Repeated measures of 24 BIA pre- and post-HD measurements were conducted over 3 
months on 20 chronic HD subjects (50% male; ages 21 - 63 years) at the King Edward 
VIII Hospital HD unit. 
Results: There was a significant difference when comparing the excess fluid estimation 
by staff and the BIA method, even when volumes over different days of measurements 
were combined (RM ANOVA; p= 0.000). In clinical practice, the difference between the 
excess fluid measured per BIA and the HD staff estimate (1.29 L difference) is 
profound. This difference was more profound in patients with a body fat percentage ≥ 
30 % and a BMI > 28 kg/m2 when compared to their leaner counterparts (p=0.000*). 
Also, within each of these groups, there is a significant difference between the staff 
estimation and the BIA measurements (p=0.000 for those with a BF ≥ 30 % and a BMI 
> 28 kg/m2, and p=0.002 for their leaner counterparts). Patients with a body fat 
percentage of ≥ 30 % and a BMI ≥ 28 kg/ m2 had a negative 3rd water space, compared 
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to those with lower body fat percentage and BMI’s. There was a significant difference 
between the two groups were statistically significant (p=0.000). 
 
Conclusion: Excess fluid measured per BIA compared with staff estimates significantly 
differed. The findings (negative 3rd water space in patients with a body fat percentage ≥ 
30 % and a BMI ≥ 28 kg/m2, and positive 3rd water space in their leaner counterparts) of 
this study suggest that there is a potential benefit of a higher body fat and BMI in End 
Stage Renal Disease (ESRD) patients on HD, versus the conventional perception of a 
healthy BMI and body fat, namely a BMI between 19 and 25 kg/m2, and body fat 
percentage between 15 and 20%. Previous studies have shown HD patients with a 
higher BF and BMI have a lower mortality risk. It is of utmost importance, that further 
studies in a larger population with ESRD on HD be conducted, to confirm this finding.  If 
confirmed, it may be pivotal in changing the dietary management of ESRD patients on 
HD. It is possible that current practice of aiming for a “healthy” body fat and BMI, maybe 
deleterious and is possibly negatively impacting on this patient populations risk for 
mortality, and long-term survival. 
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ABSTRACT (Accepted for oral presentation at the International Congress of Renal 
Nutrition and Metabolism, to be held in Japan, in April 2016). 
 
NEW INSIGHTS IN THE OBESITY SURVIVAL PARADOX IN CHRONIC CARE 
HAEMODIALYSIS PATIENTS. 
 
Downs Jane H1,2, Veldman FJ2, Kassier S2  
King Edward VIII Hospital (KEH)1, & UKZN2 
 
Background: It has been shown that chronic care haemodialysis (HD) patients 
with a high body mass index (BMI) have a survival advantage, which has 
consistently been shown to have a strong predictive correlation to decreased all-
cause mortality.  This is in stark contrast to the general population, in whom 
obesity is a significant risk factor for the development of cardiovascular disease. 
The paradoxical observation, named the obesity survival paradox was first 
reported in the 1970’s.  The mechanism of this benefit has eluded scientists for 
over three decades. 
Objective:  To assess whether there is a significant difference in the 3rd water 
space between the subjects with a higher body fat percentage and BMI when 
compared to their leaner counterparts. 
Methods: A prospective, non-randomized observational study was conducted. 
Repeated measures of 24 bioelectrical impedance analysis pre- and post-HD 
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measurements were conducted over three months on 20 chronic HD subjects 
(50% male; ages 21 - 63 years) at the King Edward VIII Hospital HD unit. 
Results: Patients with a body fat percentage of ≥ 30 % and a BMI ≥ 28 kg/ m2 
had a negative 3rd water space, compared to those with lower body fat 
percentage and BMI. The difference between the two groups was statistically 
significant (p=0.000*).  
Conclusion: Persistent excess fluid in the 3rd water space has been shown in 
previous studies to cause progressive soft tissue damage, and contributes to 
cardiac failure and brain cell damage in chronic HD patients. The findings of this 
study suggest that there is a potential benefit of a higher body fat and BMI in 
patients on chronic HD, in contrast to the conventional perception of a healthy 
BMI and body fat, namely, a BMI between 19 and 25 kg/m2, and body fat 
percentage between 15 and 20%. Previous studies have shown HD patients 
with a higher body fat percentage and BMI have a lower mortality risk. It is of 
utmost importance, that further studies in a larger population with on chronic HD 
be conducted, to confirm this finding.  The results of such a study may be pivotal 
in changing the dietary management of chronic HD patients.  It is possible that 
current practice of aiming for a “healthy” body fat and BMI maybe deleterious, 
as it has a direct impact on the risk for mortality, and long-term survival in 
chronic HD patients. 
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Chapter 1: The Problem and It’s Setting 
 
 
1.1 The Importance and Purpose of the Research 
 
Currently, in the majority of renal haemodialysis (HD) units in South Africa, the 
excess extracellular fluid to be removed in HD, is estimated by the HD unit 
staff, who compare the patient’s previous dry weight (post dialysis of the last 
dialysis session) to the current wet weight (pre-dialysis of the subsequent 
session), to determine the volume of fluid to be removed during HD.  Optimal 
fluid management plays a critical role in the management of HD patients.  
Celik et al. (2011) have demonstrated that bioelectrical impedance analysis 
(BIA) has clinical value in the estimation of dry weight and other 
haemodynamic parameters of dialysis, and hence could potentially protect HD 
patients from the risks associated with under- and over-hydration.  
 
Optimal fluid management requires accurate measurement of excess 
extracellular fluid to be removed during dialysis, and simultaneous 
minimization of potential intra- and post-dialytic adverse events (Onofriescu et 
al., 2011).    If too much excess fluid is removed during HD, this may result in 
excessive lowering of the dry weight and total blood volume, which may in 
turn result in intra-dialytic and post-dialytic complications, for example 
hypotension and muscle cramps, nausea and vomiting (Hecking et al., 2012). 
 
Chronic fluid overload in HD patients is associated with poor survival. It has 
been well documented, that excessive fluid in the extracellular fluid 
compartment, may significantly increase risk of cardiac failure and 
consequently increase the mortality risk in HD patients. The risk of 
cardiovascular (CV) mortality in dialysis patients is several times higher than 
the general population. The CV mortality risk of a 25 to 34 year old dialysis 
patient is approximately the same as an otherwise healthy 85 year old in the 
general population (Panichi & Tetta, 2011).  Inadequate fluid removal during 
dialysis may also lead to chronic fluid overload, which in turn could result in 
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hypertension, left ventricular hypertrophy and heart failure (Ion Titapiccolo et 
al., 2010). One in four dialysis patients will die suddenly. The latter is thought 
to be associated with factors related to end stage renal failure namely: 
inflammation, vascular stiffness, left ventricular hyperatrophy, coronary heart 
disease, electrolyte or fluid abnormalities or autonomic dysfunction (Green & 
Roberts, 2010).  Optimal fluid management is hence critical. 
 
Bioelectrical impedance analysis (BIA) in the assessment of hydration status 
in dialysis patients has recently been demonstrated to be a cost-effective tool 
in fluid management of HD patients (Haapio et al., 2012). Ideally, BIA should 
be utilized in conjunction with a clinical assessment, rather than in isolation 
(Woodrow & Ronco, 2012). BIA has been validated as a reliable and simple 
bedside tool in the fluid management of HD patients (Voroneanu et al., 2010).   
Zhou et al. (2010) demonstrated that the use of a calf BIA ratio not only 
significantly improved dry weight assessment in 117 HD patients, but also 
facilitated improved blood pressure control, and resulted in reductions in anti-
hypertensive medication doses. Fluid overload in renal failure is not only 
associated with increased mortality risk, but also increased hospital treatment 
costs.  Arneson et al. (2010) reported that the treatment of fluid overload in the 
Medicare haemodialysis population in the United States, cost $6372 per 
episode (41699 care episodes), resulting in a total cost of $266 million over a 
two-year period.  
 
For over thirty years, scientists have failed to demonstrate why chronic HD 
patients with a higher BMI and body fat, have a better long-term prognosis 
(Beberashvili et al., 2009; Leinig et al., 2008). One possibility is that the key/s 
to this puzzle may be found in the level of over- and under-hydration in the 
total body water and third water space. The intention of this study was to 
elucidate whether the BIA multiple frequency machine would be useful to 
estimate over- and under-hydration in clinical practice in the South African 
context, and whether it would aid in solving a puzzle that has eluded scientists 
for decades. 
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1.2 Aim and Objectives of the Study 
 
The aim of the study was to compare the excess fluid volume to be removed 
in haemodialysis patients as estimated by the HD unit staff and the volume 
measured by a multiple frequency BIA machine.  The outcome of which, 
would be used to inform future clinical practice for HD patients. 
 
The principle objective of this study was to determine whether there was a 
significant difference in the excess fluid volume to be removed in HD, 
estimated by the HD unit staff member(s) and the volume measured by the a 
multiple frequency BIA machine (Body stat Quadscan 4000®).  A difference 
would indicate that it is pertinent to review current clinical practice not only at 
King Edward VIII Hospital, but at all HD renal units in South Africa, to improve 
the quality of life and life expectancy for all HD patients. 
 
A secondary objective was to assess whether there was a significant 
difference in the 3rd water space between the subjects with a higher body fat 
and BMI when compared to their leaner counterparts. 
 
An additional secondary objective was to evaluate whether the prediction 
marker (also referred to as the Illness marker), which is an indirect value 
measured by the Bodystat Quadscan 4000®, improves post dialysis.  A value 
of 1 is the highest value and reflects fluid overload.  The integrity of cells is 
characterized by the ratio between the measured impedance values at 5 kHz 
and 50 kHz. A healthy ratio (prediction marker) is 0.85.  Unhealthy or ill 
patients have a prediction marker closer to 1, whilst more athletic and 
muscular individuals (especially highly trained athletes) tend to have a 
prediction marker of less than 0.85.   The measurement of the prediction 
marker pre- and post-dialysis will serve as an indicator of the potential health 
impact for HD patients, through the use of a more sensitive/ accurate fluid 
measurement tool in estimating the total volume of fluid to be removed during 
HD (Sobotka, 2011).  
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1.3 Study Hypothesis 
 
It was hypothesized that the excess fluid estimated by the HD staff members 
versus the amount determined by a multiple frequency BIA machine, the 
Bodystat Quadscan 4000® differ.  It was predicted that the BIA values are 
better indicators. 
 
1.4 Description of the Study Site 
 
The research was conducted at the King Edward VIII hospital, Congella, 
Durban, Haemodialysis Renal Unit. 
 
1.5 Definition of Terms 
 
 End stage renal disease: All individuals with GFR <15 mL/min/1.73 
m2 for  3 months are classified as having end stage renal disease, 
irrespective of the presence or absence of kidney damage (National 
Kidney Foundation K/DOQI Working Group, 2000). 
 Haemodialysis: “the filtering of circulating blood through a semipermeable 
membrane in an apparatus (haemodialyser or artificial kidney) to remove 
waste products: performed in cases of kidney failure” (Collins Dictionary, 
2015). 
 Intracellular fluid volume: “a fluid within cell membranes throughout 
most of the body, containing dissolved solutes that are essential to 
electrolytic balance and to healthy metabolism.  Also called intracellular 
water.” (Mosby's Medical Dictionary, 2009). 
 Extracellular fluid volume: “the fraction of body water not in cells, about 
20% of body weight; it consists of plasma water (about 4% of body 
weight), water between cells (interstitial water-lymph, about 15% of body 
weight), and water in dense bone and connective tissue (about 1% of body 
weight).” (Farlex online Medical Dictionary, 2015). 
 Total fluid volume: “About two thirds of the human body's water is held in 
its cells and the remainder is found in the extracellular compartment.  The 
extracellular fluids may be divided into three types: interstitial fluid in the 
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"interstitial compartment" (surrounding tissue cells and bathing them in a 
solution of nutrients and other chemicals), blood plasma in the 
"intravascular compartment" (the blood vessels), and small amounts of 
transcellular fluid such as ocular and cerebrospinal fluids in the 
"transcellular compartment".  The interstitial and intravascular 
compartments readily exchange water and solutes but the third 
extracellular compartment, the transcellular, is thought of as separate from 
the other two and not in dynamic equilibrium with them.” (Jacob et al., 
2009).  
 Third water space: “It the abnormal accumulation of water outside of the 
extracellular and intracellular fluid spaces that is in the interstitial space, 
for example between the skin and fascia, which is not normally perfused 
with fluids” (Farlex online Medical Dictionary, 2015). 
 Phase Angle: The phase angle is a measure of the quantity of 
metabolically active cells and the lean body cell mass, which contains 
large amounts of water and electrolytes.  Low phase angles have been 
associated with an increased risk of mortality in haemodialysis patients 
(Manlucu et al., 2010). 
 Prediction Marker: The Prediction Marker or Impedance Ratio is the ratio 
between the impedance measurement at 200 kHz and 5 kHz.  At 200 kHz 
the current is strong enough to penetrate the cell membrane and therefore 
total body water (TBW) can be measured.  However, at 5 kHz the 
membrane cannot be penetrated and only extracellular water (ECW) can 
be measured.  Intracellular water (ICW) is derived by TBW-ECW.  The 
greater the variance between the two impedance values at 5 kHz and 200 
kHz, the healthier the body cells.  To allow easy monitoring of change, 
these figures are expressed as a ratio.  A ratio closer to 1.00 indicates 
poor cellular health or extreme fluid overload (Sobotka, 2011). 
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1.6 Principal Investigator and Supervisors 
 
The principal investigator of the study was Jane Downs, Registered Dietitian, 
employed full time at King Edward VIII Hospital. 
 
The principal supervisors of the study were Professor Frederick J Veldman 
(HOD, Dietetics & Human Nutrition, UKZN) and Dr Suna Kassier (Lecturer & 
Academic Coordinator: Post-Graduate Diploma, Dietetics & Human Nutrition, 
UKZN). 
 
1.7 Study Methodology 
 
1.7.1 Study Design 
 
This study followed a prospective, non-randomized observational (multiple 
series of data per subject) design.  
 
1.7.2 Study Population and Sampling 
 
BIA measurements were conducted on 20 chronic care haemodialysis (HD) 
patients. All the patients that were on the chronic HD programme at the time 
the study was conducted, that is, non-randomized selection, were included in 
the study. Both male and female patients with an age range of 18 to 65 years 
at the King Edward VIII Hospital Renal Unit were selected. 
 
1.7.2.1 Inclusion Criteria 
 
KEH VIII chronic care HD patients, with a urine output of less than 800 ml   
per day. 
 
7 | P a g e  
 
1.7.2.2 Exclusion Criteria 
 
Pregnant patients, patients with acute renal failure, patients with advanced 
cardiac failure (specifically those with a pacemaker), and those with 
orthopaedic implants. 
 
1.8 Data Collection Procedures and Data Collection Sheets 
 
Standardized data collection and documentation procedures were followed; 
refer to addenda 1, 2, 3, 4, 5, 6, and 7. 
 
1.9 Duration 
 
The study was conducted over a 7 month period during 2014 to 2015. BIA 
measurements were conducted twice a week, that is, per dialysis session per 
week for a period of three months. 
 
1.10 Statistical Analysis  
 
The data were analysed using descriptive statistics and the generalised linear 
model of repeated measures and the analysis of variance (ANOVA) to 
account for the repeated measures on the same patients with time, using 
Statistica Version 7.1, StatSoft, Tulsa, OK, USA, and IBM Statistical Package 
for the Social Sciences (SPSS) Statistics Version 23.  A statistician was 
consulted to assist with the statistical analyses. 
 
1.11 Ethical Considerations 
 
UKZN Medical School (BREC) ethics was obtained (reference number:  
BE041/14), and concurrent written approval from the KZN Department of 
Health was also sought.  A subject code was allocated to each subject, to 
protect the subject’s identity, as well as, for each HD unit staff member who 
estimated the fluid volume to be removed, to protect their identity. 
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1.11.1 Subject Consent 
 
Each subject was individually counselled in their preferred language, 
regarding the purpose and scope of the study.  Subsequently each subject 
was provided with an information sheet stipulating the purpose and scope of 
the study. Following this, written informed consent was obtained in their 
language of choice (see addendum 8 for the English and Zulu version of the 
consent form). 
 
1.11.2 Potential Risk to the Subjects 
 
There was no potential risk to the patient. The study was essentially an 
observational study, and the BIA measurements were non-invasive.  The 
measurement of BIA is contra-indicated in pregnant women, patients with 
pace makers, and those with orthopaedic implants; hence such patients were 
excluded from the study. 
  
Usual renal unit protocols as per the study site were strictly adhered to, 
regarding patient monitoring during dialysis.  The BIA measurements did not 
influence usual practice and patient care interventions. 
 
The following risks were taken into account during the study: 
 
i. Biological risks - Nil 
ii. Psychological risks - Nil 
iii. Social Risks - Nil 
iv. Legal risks - Nil 
v. Financial risks - Nil 
vi. Other risks – None known 
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1.11.3 Risk Minimization 
 
 The following steps were taken to minimize risk: 
i. Biological risks: Usual renal HD unit monitoring during dialysis was 
strictly followed. 
ii. Psychological risks: Each subject was individually counselled in their 
language of preference before the study was commenced.  In addition, 
subjects were made aware of the fact that they are able to exercise 
their right to exit the study at any time, without any discrimination or 
dire consequences to their treatment or care. 
iii. Social Risks: There was no social risk, nor stigma associated with 
participation in this study.  The data were collected on the subjects’ 
usual clinic visits. 
iv. Legal risks: The test was non-invasive and all subjects signed a 
consent form, with a disclaimer, at the onset of the study. 
v. Financial risks: The study costs were limited (Bodystat tabs); no 
special/ additional blood tests nor any other biological tests were 
required for this study, other than those routinely used in the 
management of the HD patients. 
vi. Other risks: Nil known. 
 
1.11.4 Subjects Incentives and Reimbursement 
 
The study subjects did not receive any incentives, nor re-imbursement, as the 
research was conducted during their usual clinic visits at the regular clinic 
times. 
 
1.12 Funding and Resources 
 
The funding required for the study was for the cost of 8 electrodes for 
duplicate measurements in 25 patients over a period of 12 weeks (= 2400 
Bodystat electrodes at an estimated cost of R10 560). 
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The Bodystat Quadscan 4000® multiple frequency BIA machine, was loaned 
to the researcher by LifeMax (South African distributor) or Bodystat (UK 
manufacturer). 
 
1.13 Disclosure of Conflict of Interest 
 
The principal researcher has not received any funding/ sponsorship from 
neither LifeMax nor Bodystat. 
 
1.14 Consultation 
 
During the process of compiling the study protocol (prior to the onset of the 
study), the principal investigator consulted both Prof A. Assounga (Head of 
Nephrology, Medicinal School, UKZN) and the KEH VIII HD renal unit staff.  
These individuals strongly supported the study objectives and the potential 
benefit the results held for HD patient care. 
 
1.15 Structure of the dissertation 
 
The structure of the dissertation is as follows: 
 
Chapter 2 is a literature survey, in which the most critical information needed 
to understand and interpret the hypothesis and the results of this study, is 
examined.  Chapter 3 explains and gives the motivation behind experimental 
methods and the research tools.  The results of the study are provided in 
Chapter 4, followed by a discussion of the results of the study in Chapter 5.  
Finally, in Chapter 6, the conclusions and recommendations are made based 
on the findings of the study. 
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Chapter 2: Literature Review 
 
 
2.1 Introduction  
 
Once 90% or more of kidney function is lost, either kidney transplantation or 
dialysis is required to sustain life.  Approximately 400 000 persons in the United 
States (USA) and over 2 million persons worldwide are dependent on dialysis.  
About 90% of American patients and approximately 70% of Canadian patients 
with end stage renal disease (ESRD) are on haemodialysis (HD) (The FHN Trial 
Group, 2010).  In South Africa from 1999 to 2006, there was a 67% increase in 
deaths due to chronic kidney disease (CKD) (Moosa et al., 2015). In 2010, 
Naicker reported that there were 2070 South Africans on haemodialysis 
(Naicker, 2010).  Typically ESRD patients on haemodialysis receive HD three 
times a week.  The rationale for the latter is based on a combination of 
physiological experiments, assessments of patient acceptance, feasibility, 
logistics and costs. Mortality amongst ESRD patients on HD remains high (18 to 
20%) despite improvements in the dialysis technology, new pharmaceutical 
agents, and experience accumulated in the past 40 years since the inception of 
HD (The FHN Trial Group, 2010). 
 
More than 50% of ESRD patients die from cardiovascular disease, a risk 10 to 
20 times greater than the general population. Greater than 80% of ESRD 
patients have hypertension (HPT), a potentially modifiable cardiovascular risk 
factor, however, an estimated 70% are poorly controlled.  An expanded 
extracellular fluid volume, an increase in peripheral vascular resistance due to 
haemodynamic and trophic effects of sympathetic nerve activity and 
inflammation are key contributing factors to hypertension in ESRD (Zimmerman 
et al., 2014). 
 
Fluid management is central to the management of ESRD. Persistent fluid 
overload damages the cardiovascular system and leads to hypertension, left 
ventricular hypertrophy, congestive heart failure, pulmonary oedema, peripheral 
oedema and other adverse cardiovascular consequences (Moissl et al., 2013; 
12 | P a g e  
 
Tsai et al., 2014).  Mortality risk increases with a pre-dialysis fluid overload of 2.5 
litres (Moissl et al., 2013).  Conversely, dehydration, excessive fluid removal or 
ultrafiltration, may result in intradialytic symptoms of hypotension such as acute 
ischaemic events with recurrent episodes, potentially causing functional 
impairment and organ damage (Vasko et al., 2013).  Controlling fluid status in an 
optimal range is crucial to improve cardiovascular tolerance, quality of life and 
survival (Moissl et al., 2013).  
 
New non-invasive bedside tools, such as bioelectrical impedance spectroscopy 
(BIS) are useful in accurately and objectively assessing fluid status, versus the 
usual clinical practice of measuring pre- and post-body weight, to determine how 
much fluid to remove during haemodialysis (Moissl et al., 2013).  
 
2.2 Fluid Overload and the Consequences Thereof 
 
Severe fluid overload is defined as 15% above normal total fluid, and is 
associated independently with mortality in long-term HD patients (Wizemann et 
al., 2009).  Strict volume control has been shown to increase survival in ESRD 
patients on HD.  In addition to many traditional risk factors, such as diabetes 
mellitus, hypertension, hyperlipidaemia and advanced age, fluid overload is an 
important element in the progression of adverse clinical outcomes in dialysis 
patients.  Decreased kidney function contributes to decreased water excretion 
and excessive fluid overload.  An enlarged left atrium diameter, an indicator of 
volume overload, and impaired diastolic function, has been associated with a 
more rapid decline in estimated glomerular filtration rate (eGFR) (Tsai et al., 
2014). 
 
Fluid accumulation as assessed by weight change between dialyses or by 
relative plasma volume monitoring during dialysis predicts death and 
cardiovascular events independently of other risk factors in the HD population. 
(Zoccali et al., 2013).  Hence, hyper-hydration is a modifiable risk factor, and has 
been linked to more than a 2 fold increased mortality risk (Chazot et al., 2012).   
It is critically important that HD patients be guided on the path between fluid 
overload and dehydration, although it is difficult to achieve in practice.  Machek 
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et al. (2010) have shown that pre-dialysis blood pressure can be decreased by 
12.5 mmHg per 1 litre reduction of fluid overload over a year without an increase 
in intra-dialytic adverse events.  
 
Increased arterial stiffness might result in greater transmission of elevated 
systemic blood pressure to the glomerular capillaries, and hence aggravating 
glomerular hypertension, a key determinant of progressive kidney damage.  The 
interaction between fluid overload and arterial stiffness may be one of the major 
causes of kidney disease progression in patients with CKD (Tsai et al., 2014). 
 
2.2.1 Impact of Fluid Overload on Hypertension 
 
It has been shown in the USA, that as many as 72 % of HD patients suffer 
from hypertension despite being on anti-hypertensive medication.  
Normohydration has been described as a 1.1 litre above or below the normal 
range.  Blood pressure responds positively to volume removal when 
hypertension is fluid related.  However, progressive slow reduction of fluid 
overload is imperative, as even with modest reductions of extracellular water 
(500ml) in volume sensitive patients can be responsible for the difference 
between hypertension and vascular shock.  It has been observed that ESRD 
patients receiving HD in the USA population tend to have the highest inter-
dialytic weight gains, as well as, higher mortality rates than their European 
counterparts (Wabel et al., 2008). 
 
Slow removal of excess salt and water during dialysis has been shown to treat 
hypertension in 90% of HD patients.  Anti-hypertensive medications (including 
diuretics) have been shown to exacerbate fluid retention in HD patients.  The 
addition of each medication is associated with approximately 1 litre excess 
ECW.   The slow reduction of estimated dry weight, results in the successful 
reduction of the number of anti-hypertensive medications, and a decrease in 
blood pressure (Tapolyai et al., 2011).  Poorly controlled hypertensive patients 
undergoing haemodialysis are more likely to have large inter-dialytic weight 
gain (Vujičić et al., 2013).  In a prospective study conducted by Vujičić et al. 
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(2013), the group of patients with poor compliance, usually had more than 
four kilograms inter-dialytic weight gain. 
 
It is extremely important to take cognizance of the fact that oedema may only 
become clinically evident when there is an extracellular fluid overload of up to 
10% of body weight (Tomson, 2001).  It is concerning that fluid overload leads 
to increased mortality risk, although the clinical signs may not be evident in all 
HD patients (Chazot et al., 2012). An HD patient may also remain hyper-
hydrated despite the low inter-dialytic weight gain (Wizemann et al., 2009). 
 
2.2.2 Impact of Salt (Sodium) Intake on Fluid Intake and Fluid Overload 
 
The distribution of sodium in the body is not homogenous.  Approximately 
90% of the exchangeable sodium is found in the extracellular volume, and 
about 10% is found in the intracellular volume. The sodium concentration 
directly determines the size of the extracellular volume.  The depletion of 
sodium results in extracellular volume reduction, whilst sodium overload 
results in extracellular overload.  Hence, the extracellular volume may be 
exposed to wide and rapid variation due to salt ingestion variability (Charra, 
2007). 
 
In normal individuals, low sodium sensitivity allows for wide variations in 
extracellular volume, but not consequent significant changes in blood 
pressure.  An increase in sodium intake results in increased thirst and 
consequent increased fluid ingestion, which in turn results in an increase in 
extracellular volume (Charra, 2007).  According to Tomson (2001), sodium 
intake drives thirst, and it is physiologically impossible for a conscious patient 
to ignore thirst.  Attempts to limit fluid intake without limiting salt intake, may 
be described as an act of futility.  Hence, if a dialysis patient’s sodium intake 
exceeds the recommended restricted intake, the individual will not be able to 
resist the stimulus to drink fluids, in order to maintain serum osmolality in the 
normal range (Tomson, 2001).  
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Haemodialysis patients may experience challenges in adapting to sodium 
restrictions, due to their longstanding dietary habits and taste preferences. 
There is a need to develop culturally diverse education tools and interventions 
to decrease dietary sodium intake in HD patients. Further quality improvement 
studies which assess patient and patient family interventions to decrease 
dietary sodium intake, are necessary (Weiner et al., 2014). 
 
Serum osmolality which is primarily determined by sodium levels, stimulates 
thirst.  Elevated sodium levels not only drive thirst, but draw intracellular fluid 
into the extracellular space, and when that is saturated, results in an increase 
in third water space, presents clinically as oedema (Tomson, 2001; Levin et 
al., 2010).  
 
Small amounts of water are lost in the form of perspiration, but these losses 
are usually limited to 500ml per day, and possibly less in cooler climates.  
Small amounts of water are also lost in the stool, in individuals with normal 
bowel function.  The average healthy individual (70kg) contains approximately 
40 litres of water. Approximately two thirds of the water is found in the 
intracellular volume, and one third in the extracellular volume, most of which 
comprises of the interstitial fluid.  The circulating volume is about 4 litres, of 
which the plasma water comprises approximately 50% (2 litres); the latter is 
dependent on the haematocrit (Tomson, 2001). 
 
Fluid weight gained between dialysis sessions, tends to remain in the 
extracellular space.  A high extracellular fluid sodium concentration will tend to 
result in a flux of water from the cells, resulting in intracellular dehydration, 
which in turn may result in rebound hypernatraemia post-dialysis.  The latter 
results in an increased thirst post-dialysis, with increased inter-dialysis fluid 
weight gain. Hence, in the absence of adequate sodium intake restriction, the 
vicious cycle is perpetuated (Tomson, 2001). 
 
Excessive fluid intake, may result in hyponatraemia and a consequent 
increased intracellular volume, which may result in cerebral oedema (Tomson, 
2001).  Recently, persistent cerebral oedema has been shown to cause 
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progressive irreversible brain damage in ESRD patients on dialysis.  Kong et 
al. (2014) recently reported that HD patients had diffuse interstitial brain 
oedema and moderate white matter integrity disruption, which correlated with 
cognitive dysfunction.  Similarly, Zhang et al. (2015) have observed that brain 
oedema and white matter demyelination resulted in structural damage of the 
radiation and associative fibre tracts. It was further suggested that the 
cognitive deficits in ESRD patients may be caused by the fibre tract damage. 
 
Concern has been expressed that avoiding added salt in cooking and at the 
table, is insufficient to restrict sodium intake in ESRD patients, due to the wide 
availability of processed foods with a high salt content (>600 mg sodium per 
100 g), including in commonly eaten foods, for example, bread, cereals, and 
in fast foods (He & MacGregor, 2010).  Haemodialysis patients are often 
reliant on food provided/ eaten by the family, in which the use of stock cubes 
and flavourants such those containing monosodium glutamate are common 
place. There is a need to not only educate the patient but also the family on 
how to flavour food without salt, using herbs (not high in potassium) and salt 
free natural spices (pers obs).  The intake of salt in healthy individuals should 
ideally be limited to 6 g per day (Charra, 2007); whilst ESRD patients on HD 
need to limit their sodium intake to under 2000mg sodium per day (which is 
equivalent to 5 g sodium chloride) (Akbari et al., 2015). 
 
Sodium intake not only drives fluid intake but effects blood pressure levels.  
Approximately 90% of ESRD patients have hypertension at the time of HD 
initiation.  Excess sodium has been described as a dominant factor in 
hypertension in ESRD (Charra, 2007).   
 
It has been shown that a moderately sodium restricted diet usually results in 
an inter-dialytic weight gain of less than 2 kg, whilst an unrestricted diet 
(approximately 10 to 15 g salt per day) results in a weight gain of up to 4 kg or 
more between dialysis sessions.  Excessive inter-dialytic weight gain and the 
prevalence of hypertension have been shown to be strongly related (Charra, 
2007). 
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Not only dietary sodium, but also dialysate sodium concentration is correlated 
with inter-dialytic weight gain and blood pressure control (Beduschi et al., 
2013; Hecking et al., 2012).  The importance of reducing sodium overload in 
order to reduce or prevent fluid overload, has been strongly emphasized, and 
more recently sodium individualization (in terms of dialysate sodium content) 
has been encouraged in practice. The latter needs to be implemented with 
caution, as a lower sodium prescription can potentially cause osmotic 
disequilibrium, and consequently be hazardous (Hecking et al., 2012).  
Manlucu et al. (2010) have suggested that increased sodium removal during 
dialysis, and through reduced salt intake, may lead to decrease water 
consumption.   
   
It has been suggested that individualized sodium prescriptions may improve 
clinical outcomes, through the benefits of reduced extracellular fluid volume, 
and the improvement of cellular health.  Cellular health can be measured 
indirectly per BIA; the prediction marker (ratio of impedance) reflects the 
health of cells (Manlucu et al., 2010). 
 
It has been recently reported that excess sodium without osmotic activity is 
stored in the skin in concentrations of 180 to 190 mEq/L in the skin.  This 
sodium is bound to glucosaminoglycans, and the sodium stored in the skin 
could potentially function as a buffer to exogenous sodium loading.  It is also 
possible that when these sodium stores are released into the circulation, may 
cause hypervolemia and oxidative stress.  The latter may be aggravated by a 
progressive decrease in connective tissue mass which occurs in ageing and 
catabolism, hence reducing the skins capacity to act as a sodium reservoir 
(Levin et al., 2010).   This possibly plays a role in increased risk for mortality 
in older HD patients (pers obs). 
 
2.2.3 Gastrointestinal Oedema 
 
In ESRD patients with chronic congestive cardiac failure with fluid overload, 
bowel wall oedema may contribute to increased gut permeability and bacterial 
endotoxin translocation.  Inflammation suppresses water channel aquaporin1, 
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a molecular counterpart of the ultra-small pore responsible for transcellular 
water permeability (Tsai et al., 2014). 
 
2.2.4 Uremic Cardiomyopathy 
 
Uremic cardiomyopathy is considered to be the irreversible end result of the 
prolonged damaging effect of factors associated with end stage renal failure.  
Despite an ESRD patient previously being severely hypertensive, the blood 
pressure is often normal or low when the diagnosis of cardiomyopathy is 
made.  Severe cardiac enlargement and systolic dysfunction (low ejection 
fraction) are usually used to describe uremic cardiomyopathy, and are 
indicative of a particularly a poor prognosis.  Management of poor volume 
control due to excess inter-dialytic fluid weight gain, is critical in preventing 
uremic cardiomyopathy (Tȍz et al., 2007). 
 
2.3 Hypertension 
 
Owing to the high prevalence of 60 to 90% of ESRD patients having HPT, the 
2005 National Kidney Foundation Kidney Diseases Outcomes Quality Initiative 
(K/DOQI) clinical practice guidelines (CPG) recommended pre-and post-dialysis 
blood pressure (BP) of less than 140/90 and 130/80 mm Hg.  These guidelines 
are based in part on data collected in the non-dialysis population.  Conversely, it 
has been consistently observed in observational studies, ESRD patients have 
elevated mortality with persistently low blood pressures.  It has been speculated 
that ESRD patients with a low BP, have co-existing illness such as poor 
ventricular function which lowers BP and poor general health (Robinson et al., 
2012). 
 
End stage renal disease patients with a pre-dialysis systolic BP of greater than 
160 mm Hg have increased mortality, as do ESRD patients with a pre-dialysis 
systolic BP of less than 130 mm Hg.  Hence, it is important ERSD management 
guideline to maintain pre-dialysis systolic BP between 130 and 159 mm Hg.  
Treatment with anti-hypertensive medication has been associated with longer 
survival and fewer CV complications.  However, modulation of BP in ESRD 
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patients’ needs to be done with caution, as too aggressive modulation may 
contribute to myocardial stunning, associated with intra-dialytic hypotension, 
which is likely to be harmful (Robinson et al., 2012). 
 
There are various potential causes for blood pressure variability in HD patients, 
namely: baroreceptor dysfunction, aortic stiffness and variations in intravascular 
volume. The variability in BP can result in increased risk for cerebral small blood 
vessel disease, cerebral haemorrhage and sudden cardiac death in HD patients, 
compared to the general population (Selvarajah et al., 2014). 
 
According to Curatola et al. (2011), either more frequent or longer in duration 
HD, and improved efforts to increase low salt diet compliance, are required to 
decrease the high prevalence of hypertension in the HD population. 
  
2.4 Dry Weight 
 
Dry weight has been conventionally defined as the lowest body weight that can 
be tolerated without developing intra-dialytic and inter-dialytic symptoms of 
hypovolemia or symptoms of dehydration, and in the absence of overt fluid 
overload (Vasko et al., 2013; Onofriescu et al., 2012; Vujičić et al., 2013). 
 
2.5 The Association between Body Mass and Mortality 
 
It has been shown that chronic care HD patients with a high body mass index 
(BMI) have a survival advantage.  This patient group has consistently been 
shown to have a strong predictive correlation to decreased all-cause mortality.  
The latter is in contrast to the general population, where the opposite is true, 
where obesity has been shown to be a risk factor in the development of 
cardiovascular disease (Beberashvili et al., 2009).  The paradoxical observation, 
named the obesity survival paradox or reverse epidemiology regarding a 
decrease in mortality with a high BMI was first reported in the 1970’s (Yen et al., 
2010).  The mechanism of this benefit has eluded scientists for over three 
decades. 
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Beberashvili et al. (2009) have reported that HD patients with a higher BMI had a 
higher lean body mass, a higher phase angle and a lower extracellular mass 
(ECM) to body cell mass (BCM) ratio.  Conversely, a low BMI and loss of muscle 
mass have been associated with morbidity and mortality in chronic kidney 
disease (Leinig et al., 2008).  Interestingly, in a study conducted by Leinig et al. 
(2008), a stronger correlation between BMI and fat mass (FM) versus BMI and 
lean body mass (LBM), in survival advantage in patients with chronic kidney 
disease was observed.  Increased visceral fat mass has been shown to predict 
poor outcome in male but not female HD patients (Ikizler, 2008).   Tapolyai et al.  
(2011) reported that the percentage body fat has a reverse relationship with over 
hydration, and with every 10% increase in body fat, there is a 1.2 L decrease in 
over hydration, and suggested that patients with a greater body fat and higher 
BMI have less fluid retention. 
 
Chronic care HD patients tend to experience anorexia and catabolic effects of 
dialysis, and have inappropriately increased basal energy expenditure, which 
results in a significant negative energy balance.  This in turn results in loss of 
weight and subcutaneous adipose tissue over time, in HD patients who survive 
over a decade.  This patient group often experience a decrease in nutrient 
supply or intake, altered metabolism, and increased nutrient requirements 
(Ikizler, 2008).  Segall et al.  (2009) have shown that not only advancing age, 
diabetes and heart failure, but also a body fat percentage of less than 15 % and 
a phase angle of less than 6 degrees were associated with a significantly 
increased risk of death in HD patients. 
 
2.6 Bioelectrical Impedance Analysis 
 
Bioelectrical impedance analysis (BIA) estimates body composition, including 
hydration status, by measuring the body’s resistance and reactance to electrical 
current (Onofriescu et al., 2012).  Bioelectrical impedance analysis is a relatively 
inexpensive, safe, and portable tool, and easy to perform without extensive 
training, to assess both body fluid and nutritional status. It provides an indirect 
measure of body composition, and the accuracy of BIA is largely determined by 
mathematical models and their assumptions, which have essentially been 
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validated in Caucasian populations without renal disease (Oei & Fan, 2015).  BIA 
spectroscopy has been found to be both highly reproducible and have a high 
specificity (Garagarza et al., 2013).  The use of BIA to measure muscle and fat 
mass has been validated by magnetic resonance imaging (MRI) and maybe 
used routinely. After years of BIA research in HD patients, it is now increasingly 
used clinically (Kotanko et al., 2008). 
 
The nutritional assessment of HD patients is an important aspect of the 
management of these patients, but clinically may be quantitatively challenging. 
Body composition alterations which are associated with malnutrition over time in 
HD patients, are strong predictors of mortality. Hence BIA is not only important 
for fluid management but also nutritional management of HD patients (Kaysen et 
al., 2005). 
 
Clinical signs such as oedema, HPT and pulmonary congestion do not correlate 
well with the degree of fluid over load, whilst traditional reference methods based 
on dilution techniques using deuterium or sodium bromide, are invasive, 
expensive, labour intensive and have not been adopted in clinical practice (Oei & 
Fan, 2015).  Fluid assessment using BIA measurement has been used in HD 
patients for more than 4 decades (Anand et al., 2012). 
 
BIA is based on the principle of bioelectrical impedance (the vector sum of 
resistance and reactance) (Caravaca et al., 2011). Single or mono frequency BIA 
utilizes a frequency of 50 Hz, which passes through both intra- and extracellular 
fluid.  Equations to estimate total body water are based on the volume conductor 
model and multiple regression analysis (Oei & Fan, 2015).  Whilst multiple-
frequency BIA spectroscopy is more developed and has complex theoretical 
bases, which allow for more accurate determination of total body water (TBW), 
and measure the distribution of water between the intracellular and extracellular 
spaces, and in the recent decade been extensively used in HD patients 
(Caravaca et al., 2011).  The measurement of extracellular water (ECW) is 
especially important in HD patients, as most of the excess fluid removed in HD is 
from the ECW (Chen et al., 2014).  Multiple frequency BIA measures frequencies 
from 5 to 1000 Hz, that is, a wide range of frequencies (Moon et al., 2010).   
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BIA has been successfully used to guide HD patients toward normohydration 
and better blood pressure control (Onofriescu et al., 2014).  In a randomized 
controlled parallel-group study conducted Onofriescu et al. (2014), a significant 
difference in survival, BP and fluid overload between the bioelectrical impedance 
group and the clinical methods (control) group was demonstrated after a 2.5 year 
intervention period.  The extracellular water to total body water ratio (as a marker 
of over hydration) was shown to be an independent predictor of mortality, with a 
hazard ratio (HR) of 2.1, second only to that related to diabetes (HR = 2.7).  BIA 
was shown to be a useful tool in achieving a true dry weight, with consequent 
improvements in BP control, arterial stiffness, left ventricular hypertrophy, with 
an overall reduction in mortality. 
 
Similarly, Hur et al. (2013)  in a prospective randomized controlled study, after 
12 months, found fluid status in the intervention group (BIA monitored) was 
significantly lower, with improvements in cardiovascular parameters, namely, a 
decrease in pre-dialysis and ambulatory BP, decrease in arterial stiffness and a 
decrease left ventricular mass index.  
 
Anand et al. (2012) found that compared to using body weight changes pre- and 
post HD, BIA is a more sensitive measure in measuring changes in body fluid, 
with a larger dynamic range.  BIA was recommended as a cost effective simple 
non-invasive method for monitoring fluid especially for HD patients with a recent 
acute decompensatory heart failure event, providing an early diagnostic 
opportunity, and allowing for early intervention to avoid hospitalization and 
reduce the corresponding risk of mortality.   
 
Vujičić et al. (2013) found BIA allows for more effective management of fluid 
status and BP control in patients on maintenance HD.  The BIA measurements 
of over hydration were used as a tool to intervene in fluid overloaded patients, to 
achieve better dry weights and improved BP.  In a study conducted by Caravaca 
et al. (2011), the findings suggested that BIA aids in identifying changes in 
hydration status in CKD patients, which may not be fully appreciated through 
clinical and biochemical assessment. 
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2.6.1 Phase Angle 
 
Phase angle is a bioelectrical parameter associated with nutrition, and has a 
prognostic value in patients with renal failure (Teruel-Briones et al., 2012).  
The phase angle is a measure of the quantity of metabolically active cells and 
the lean body cell mass, which contains large amounts of water and 
electrolytes. Low phase angles have been associated with an increased risk 
of mortality in haemodialysis patients (Manlucu et al., 2010).  Caravaca et al. 
(2011) observed that HD patients with a phase angle above the mean value of 
5.3 degrees, had a better survival than those with a low angle.  The predictive 
strength of mortality risk of the phase angle was also demonstrated with an 
increase in age in the subjects in this study.  Whilst the Spanish researchers 
Abad et al. (2011)  found an improved survival benefit associated with a 
phase angle of 8 degrees, however, there was a high mortality rate in this 
study, 61 % (n = 100) of the subjects had demised at the 6 year follow-up.  
 
In healthy individuals, the cell membrane consists of a layer of non-conductive 
lipid material sandwiched between two layers of conductive protein molecules.  
The structure of cell membrane allows for capacitive element function, and 
hence when exposed to alternating currents, function as capacitors.  
Theoretically, reactance is a measure of the volume of cell membrane 
capacitance and an indirect measure of the intracellular volume or body cell 
mass.  Body fat, total body water and extra cellular water provide electric 
resistance to an electrical current.  Cell membranes and tissue interfaces 
provide capacitive reactance (Kumar et al., 2012). 
 
The phase angle is a linear method of measuring the relationship between 
electric resistance and reactance in a series or parallel circuits.  The phase 
angle is derived from the tangent value of the ratio of reactance versus 
electric resistance (Kumar et al., 2012).  The latter is indicative of alterations 
in the integrity of cell membranes and intercellular space.  The phase angle 
for healthy individuals will range from 3 to 10 degrees, depending on gender.  
Lower phase angles appear to be consistent with low reactance, cell death, or 
loss of the selective permeability of cell membrane (Costa de Oliveira et al., 
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2010).  There is a significant difference in phase angle between healthy and 
disease states.  The phase angle increases with improving clinical status 
(Kumar et al., 2012). 
 
2.6.2 Prediction Marker 
 
The Prediction Marker or Impedance Ratio (which was previously referred to 
as the illness marker) is the ratio between the impedance measurement at 
200 kHz and 5 kHz.  At 200 kHz the current is strong enough to penetrate the 
cell membrane and therefore total body water (TBW) can be measured.  
However, at 5 kHz the membrane cannot be penetrated and only extracellular 
water (ECW) can be measured.  Intracellular water (ICW) is derived by TBW-
ECW. The greater the variance between the two impedance values at 5 kHz 
and 200 kHz, the healthier the body cells. To allow easy monitoring of change, 
these figures are expressed as a ratio. A ratio closer to 1.00 indicates poor 
cellular health or extreme fluid overload (Sobotka, 2011). 
 
2.7 Conclusion and Recommendations 
 
Fluid management is of utmost importance in the management of ESRD.  
Persistent fluid overload damages the cardiovascular system, and leads to 
hypertension, left ventricular hypertrophy, congestive heart failure, pulmonary 
oedema, peripheral oedema and other adverse cardiovascular consequences 
(Moissl et al., 2013; Tsai et al., 2014).  Current practice in most South African 
haemodialysis units is to use the pre- and post-dialysis body weights to 
determine the volume of fluid to be removed during dialysis.  
 
Recent studies have shown that BIA is a useful, cost effective and reliable tool in 
guiding both HD staff and patients, so that the patients achieve an optimal dry 
weight, without compromising lean and fat weight.  In order to evaluate whether 
BIA needs to be implemented as standard practice in South African HD units, it 
is extremely relevant that the difference between standard practice and BIA 
measurements in the estimation of excess fluid be investigated.  The effective 
reduction of third water space could potentially not only prevent or delay the 
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onset of cardiac failure, but also reduce the prevalence of hypertension and 
consequently significantly reduce the mortality risk in this group of patients. 
 
Differences in the BIA pre-and post-illness marker may demonstrate the positive 
effects of regular HD.  Whilst investigating the differences in excess fluid, third 
water space, intracellular and extracellular fluid in the HD patients with a higher 
BMI and body fat percentage versus their leaner counterparts, may shed some 
illuminating light on the mystery that has eluded scientists for the past 30 years, 
namely, the reason the HD patients with a higher body fat percentage and BMI 
have a lower mortality risk. 
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Chapter 3: Methodology 
3.1 Introduction 
 
In this chapter, an overview is given of the study design, the sampling  
procedure, as well as, the methods and measuring instruments that were used 
for data collection in the current study.  The sections on study population and 
sample selection and the inclusion and exclusion criteria, provides an overview 
of eligibility for participation and the criteria that were used to select subjects.  
This is followed by the methods and materials which includes a detailed 
description of how the data was collected.  This was followed by how the data 
was statistically analysed.  Lastly, the reliability and validity of the data was 
discussed in addition to ethical considerations.   
 
3.2 Research Design 
 
This study followed that of a prospective, non-randomized observational 
(multiple series of data per subject) design over a period of 7 to 8 months, 
recruited haemodialysis patients attending the King Edward VIII Hospital Renal 
Unit. Pre- and post-bioelectrical impedance analysis (BIA) measurements using 
a multiple frequency BIA machine were conducted on the patients.  
 
3.3 Study Population and Sampling 
 
 All the patients who were on the chronic programme during the study period, 
that is, non-randomized selection, both males and females with an age range of 
19 to 63 years at the KEH VIII Renal Unit were requested to volunteer for the 
study.  Two subjects demised during the study, and one subject dropped out of 
the study. The data of the latter patients were not included in the data analyses. 
The data of 20 subjects were analysed. 
 
3.3.1 Inclusion Criteria 
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KEH VIII chronic care HD patients, with a urine output of less than 800 ml per 
day were included in the study. 
 
3.3.2 Exclusion Criteria 
 
Pregnant patients, patients with advanced cardiac failure (specifically those 
with a pacemaker) and those with orthopaedic implants were excluded from 
the study. 
 
3.4 Data Collection Procedures and Sheets 
 
Standardized data collection procedures were followed, and standardized 
data records were utilized. Refer to addenda 1, 2, 3, 4, 5, 6, and 7 for the data 
collection procedures and records. 
 
3.4.1 Anthropometry Measurements 
 
3.4.1.1 Measurement of Height and Weight 
 
Standardized procedures were followed in the measurement of the 
patients’ height and weight. Refer to addenda 2 and 3 for the detailed 
procedure followed. The Frankfort Horizontal Plane method was used for 
measuring the height. The electronic scale was calibrated on a weekly 
basis, as described in addendum 4. 
 
3.4.1.2 Measurement of Bioelectrical Impedance 
 
The bioelectrical impedance was performed with a multiple frequency BIA 
machine (Bodystat Quadscan 4000 ®, United Kingdom).  Prior to the BIA 
measurement, the patients were requested to remove all jewellery.  The 
patients laid in a supine position for approximately 10 minutes on a non-
conductive surface. During both the inclusion process and prior to the first 
BIA measurement, a medical history was taken to ascertain whether the 
patient had a pace maker, any orthopaedic implants, or was pregnant.  
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The patients’ legs were separated at a 30 to 40 degree angle.  The 
procedure made use of the right arm and leg, unless the presence of a 
fistula in the right arm. The left side of the body was then used for all tests.  
 
Electrodes were placed at the dorsum of the hand and foot on the 
metacarpal and metatarsals, respectively.  The reading electrodes were 
placed between the medial and lateral malleolus of the same side of the 
body.  Patients were requested not to move nor talk during the test.  All the 
tests (both pre- and post-) were conducted by the principal investigator.  A 
single measurement was taken both prior to HD, and 15 minutes post 
dialysis. 
 
The HD unit staff were blinded; the BIA results were not discussed during 
the study period with the HD staff.  The results were only explained to the 
patients, once the patients were on HD, to prevent the patients from 
influencing the HD staff’s usual practice in calculating fluid to be removed 
during HD. 
 
3.5 Duration 
 
The study was conducted over a 7 month period during 2014 to 2015, in 
which the consecutive pre- and post- HD BIA measurements were performed 
on each subject twice or three times per week (depending on the subjects 
frequency of dialysis), that is, per dialysis session per week for a period of 
three months (12 weeks). 
 
3.6 Statistical Analysis 
 
The data were analysed using descriptive statistics and the generalised linear 
model of repeated measures analysis of variance (RM ANOVA) using 
Statistica Version 7.1, StatSoft, Tulsa, OK, USA, and IBM Statistical Package 
for the Social Sciences (SPSS) Statistics Version 23, to account for the 
repeated measures on the same patients over time.  
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3.7 Ethical Considerations 
 
UKZN Medical School Biomedical Research Ethics Committee (BREC) ethics 
approval was obtained (Reference number: BE041/14), and concurrent 
written approval from the KZN Department of Health was sought, and issued.  
A subject code was allocated to each subject, to protect the subject’s identity, 
as well as, for each HD unit staff member who estimated the fluid volume to 
be removed, to protect their identity. 
 
3.7.1 Subject Consent 
 
Each subject was individually counselled in their preferred language, 
regarding the purpose and scope of the study.  Subsequently, each subject 
was provided with a written information sheet which explained the purpose 
and scope of the study.  Thereafter, written informed consent was obtained in 
the subject’s language of choice. Refer to addendum 8 for a copy of the 
English consent form, and the Zulu version of the consent form. 
 
3.7.2 Potential Risks to the Subjects 
 
There was no obvious potential risk to the patient.  The study was of an 
observational nature, and the BIA measurements were non-invasive.  The 
measurement of BIA is contra-indicated in pregnant women, patients with 
pace makers and in those with orthopaedic implants; hence such patients 
were excluded from the study. 
 
Usual renal unit protocols practiced at the study site were strictly adhered to, 
regarding patient monitoring during dialysis.  The BIA measurements did not 
interfere with usual practice and patient care interventions. 
 
I. Biological risks – Nil 
II. Psychological risks – Nil 
III. Social Risks – Nil 
IV. Legal risks – Nil 
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V. Financial risks – Nil 
VI. Other risks – None known 
 
3.7.3 Risk Minimization 
 
The following steps were taken to minimize risk: 
I. Biological risks: Usual renal HD unit monitoring during dialysis was 
strictly followed. 
II. Psychological risks: Each subject was individually counselled in their 
language of preference before the study commences.  In addition, 
subjects were made aware of the fact that they are able to exercise 
their right to exit the study at any time, without any discrimination or 
dire consequences to their treatment or care. 
III. Social Risks: There was no social risk, nor stigma associated with 
participation in this study.  The data were collected on the subjects’ 
usual clinic visits. 
IV. Legal risks: The test was non-invasive and all subjects signed a 
consent form, with a disclaimer, at the onset of the study. 
V. Financial risks: The study costs were limited (Bodystat tabs); no 
special/ additional blood tests nor any other biological tests were 
required for this study, other than those routinely used in the 
management of the HD patients. 
VI. Other risks: Nil known 
 
3.7.4 Incentives and Reimbursement 
 
The study subjects did not receive any incentives, nor re-imbursement, as the 
research was conducted on their usual clinic visits at the usual clinic times. 
 
3.8 Reduction of Bias 
 
The researcher did not discuss the BIA measurement results with the HD staff 
during the duration of the study, to reduce potential bias.  The HD staff 
followed the standard operating procedures in calculating the amount of fluid 
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to be removed during dialysis. 
 
3.9 Funding and Resources 
 
The funding required for the study was the cost of 4 tabs x 2 measurements 
per subject x 25 patients x 12 weeks = 2400 Bodystat tabs (Actual cost = 
R10560). 
 
The Bodystat Quadscan 4000® multiple frequency BIA machine, was loaned 
to the researcher by LifeMax (South African distributor) from Bodystat (United 
Kingdom manufacturer), and was returned upon completion of the data 
collection. 
 
3.10  Disclosure of Conflict of Interest 
 
The principal researcher has not received any funding/ sponsorship from 
neither LifeMax nor Bodystat.  
 
3.11 Consultation 
 
During the process of compiling the study protocol (prior to the onset of the 
study), the principal investigator consulted both Prof A. Assounga (Head of 
Nephrology, Medicinal School, UKZN) and the KEH VIII HD renal unit staff.  
These individuals strongly supported the study objectives and the potential 
benefit the results held for HD patient care. 
 
3.12 Summary 
 
This study Prospective, non-randomized observational (multiple series of data 
per subject) study. UKZN Medical School Biomedical Research Ethics 
Committee (BREC) ethics approval was obtained (Reference number: 
BE041/14), and concurrent written approval from the KZN Department of 
Health was sought, and issued.  Pre- and post- BIA repeated consecutive 
measurements using a multiple frequency BIA machine (Bodystat Quadscan 
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4000 ®) were conducted over a 12 week period, on 23 chronic care HD 
patients (all the patients who were on the chronic programme during the study 
period, that is, non-randomized selection) both males and females with an age 
range of 19 to 63 years at the KEH VIII Renal Unit. Two patients demised and 
one dropped out before the completion of the data collection; the data for 20 
subjects (48 BIA measurements per subject) were analysed. A total of 960 
BIA tests were conducted during the study period. The HD unit staff were 
blinded; the BIA results were not discussed during the study period with the 
HD staff.  The usual practice of determining fluid to be removed was recorded 
for each pre-HD test. The latter was compared to the pre-HD measurement of 
excess fluid to be removed. 
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Chapter 4: Results 
 
4.1 Introduction 
This chapter presents the results of the study, of which the primary aim was to 
compare the excess fluid volume to be removed in haemodialysis patients as 
estimated by the HD unit staff and the volume measured by a multiple frequency 
BIA machine, and to determine whether there were statistically significant 
differences between the two methods of assessing the excess fluid to be 
removed. 
 
4.2 Study Population Demographics 
 
Pre- and post-bioelectrical impedance analysis (BIA) measurements were 
conducted on 23 chronic care haemodialysis (HD) patients with an age range of 
19 to 63 years at the King Edward VIII Hospital (KEH VIII) Renal Unit. Two 
patients demised during the study, and one subject dropped out of the study. 
The data of the latter patients were not included in the data analyses.  An equal 
number of men and women (n = 10 for each gender, respectively) were recruited 
to participate in the study. 
 
All the patients had pre-existing hypertension prior to requiring HD. Two subjects 
were human immunodeficiency virus (HIV) positive and were on anti-retroviral 
treatment. One patient was diagnosed with systemic lupus erythematosus (SLE), 
one with diabetes (Type II), and one was diagnosed with a congenital cardiac 
disease.  
Table 1: Demographic profile of the study sample 
  
Variable 
Mean ± SD* 
Range 
Minimum Maximum 
Age (years) 46.45 (10.75) 20 63 
Weight (kg) 68.13 (9.98) 52.2 88.6 
Height (cm) 160.86 (7.43) 144 180 
BMI (kg/m2) 26.5 (4.33) 20.1 33.7 
     * Standard Deviation 
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4.2.1 Baseline Serum Albumin 
 
Hypoalbuminaemia has been described as an indicator of malnutrition and 
inflammation and a risk factor for kidney disease progression in chronic 
kidney disease (Tsai et al., 2014).  The lower limit of the normal blood serum 
albumin concentration is considered to be 35 g/L.  A serum albumin of ≥ 38 
g/L however, is associated with a better survival in the maintenance of the HD 
population (Sridhar & Josyula, 2013). Seventy five percent (n = 15) of the 
sample population had a baseline serum albumin concentration of below the 
lower limit of the normal reference range of 35 g/L. However, all of these 
patients fell within the range of 20 to 35 g/L, which is defined as moderately 
depleted, (refer to Figure 1).   
 
 
Figure 1:  Baseline serum albumin (g/L) levels of the patients tested; number of 
observations versus the lower normal range as indicated by the arrow.  
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4.2.2 Pre-Dialysis Systolic Blood Pressure 
  
Both end stage renal disease patients with a pre-dialysis systolic blood 
pressure (BP) of greater than 160 mmHg and end stage renal disease (ESRD) 
patients with a pre-dialysis systolic BP of less than 130 mmHg have been 
reported to carry a risk of increased mortality. Hence, it is an important ERSD 
management guideline to maintain pre-dialysis systolic BP between 130 and 
159 mmHg (Robinson et al., 2012). Pre-HD systolic BP is generally utilized to 
make clinical decisions regarding the management of blood pressure; although 
home BP monitoring has been shown to be of greater prognostic value, in 
terms of mortality, as well as serving as a marker for the presence of left 
ventricular hypertrophy associated with cardiac failure (Shafi et al., 2014; 
Alborzi et al., 2007). The pre-HD systolic blood pressure measurements 
collected over a number of days and ideal range are illustrated in Figure 2. The 
majority of the patients in this study had a mean pre-HD systolic BP that fell 
within the normal range. However, some outliers (both over and above the 
normal reference range) were present in the study. 
 
 
 
Figure 2: Pre-haemodialysis blood pressure readings of the patients over the 
number of days versus the ideal range for chronic HD patients as 
indicated by the two arrows.  
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4.2.3 Phase Angle 
 
The phase angle for healthy individuals ranges from 3 to 10 degrees, 
depending on gender.  Lower phase angles appear to be consistent with low 
reactance, cell death, or loss of the selective permeability of the tissue cell 
membranes. (Costa de Oliveira et al., 2010).  Low phase angles have been 
associated with an increased risk of mortality in haemodialysis patients 
(Manlucu et al., 2010). The pre-haemodialysis median phase angle measured 
over 24 days is reported in Figure 3. Although the median fell in the range of 
that described for healthy individuals, it was less than 5.3. Caravaca et al. 
(2011) observed that HD patients with a phase angle above the mean value of 
5.3 degrees, had a better survival when compared to those with a lower 
phase angle. 
 
 
Figure 3: Pre-HD phase angle of the patients repeated measure over days. 
 
Patients with a higher body fat (BF) percentage (≥ 30%) and a BMI of  
≥ 28 kg/m2 had a slightly higher mean phase angle when compared to that of 
the leaner patients (p=0.539; t-test for equality of means), suggesting a 
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tendency towards a healthier cell mass in the group with a higher body fat and 
BMI (refer to Figure 4).  
 
 
Figure 4: The difference in pre-HD phase angle between the patients with a body fat 
percentage of ≥ 30 % and a BMI of ≥ 28 kg/m2, versus the leaner patients.  
The trend shown demonstrates the median phase angle of higher body fat 
and BMI patients was consistently higher than that of the leaner patients, 
suggesting a healthier cell mass in the group with a higher body fat and 
BMI, over time. 
 
4.3  Comparison of the Excess Fluid Estimation by Staff and the 
BIA Measurement 
 
There was a significant difference when comparing the excess fluid estimation 
by staff and the BIA method, even when volumes over different days of 
measurements were combined (RM ANOVA; p= 0.000). In clinical practice, 
the difference between the excess fluid measured per BIA and the HD staff 
estimate (1.29 L difference) is profound. This difference was more profound in 
patients with a body fat percentage ≥ 30 % and a BMI > 28 kg/m2 compared to 
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their leaner counterparts (p=0.000*; Fig. 5 & 6). Also, within each of these 
groups, there is a significant difference between the staff estimation and the 
BIA measurements (p=0.000 for those with a BF ≥ 30 % and a BMI > 28 
kg/m2, and p=0.002 for their leaner counterparts).  
 
 
Figure 5:  The pre-haemodialysis BIA measurement of the excess fluid (total fluid 
minus the maximum normal range); the patients with a BMI ≥ 28 kg/m2 
and a body fat percentage of ≥ 30 % versus the leaner patients, shown 
over the number of days. 
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Figure 6: The fluid to be removed as calculated by the HD staff as per usual practice 
of taking into account the patients’ pre-HD and last post-HD body weight. 
The patients with a BMI of ≥ 28 kg/m2 and a body fat percentage of ≥ 30 
% consistently required less fluid to be removed, when compared to their 
leaner counterparts.  
 
 
4.4 Difference in Third Water Space 
 
Patients with a body fat percentage of ≥ 30 % and a BMI ≥ 28 kg/ m2 had a 
negative 3rd water space, compared to those with lower body fat percentage and 
BMI’s. There was a significant difference between the two groups were 
statistically significant (p=0.000*; Figure 7). 
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Figure 7:  The difference in pre-HD third water space between the patients with a 
body fat percentage of ≥ 30 % and a BMI of ≥ 28 kg/m2, versus the 
leaner patients.  The trend shown demonstrates the mean of higher body 
fat and BMI patients’ 3rd water space is negative, whilst the leaner 
patients had a positive 3rd water space, which is associated with 
deleterious side-effects in the long-term. 
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4.5 Intracellular Fluid 
 
All patients’ intracellular fluid was below the normal range despite their hydration 
status.  There was no significant difference when combined effects including days 
were considered but there was a significant difference between pre-dialysis value 
and normal intracellular fluid level (p=0.003*), as illustrated in Figure 8. 
 
 
Figure 8: Pre-HD intracellular fluid versus the normal range, illustrating the patients’ 
intracellular fluid was consistently below the normal range, irrespective of 
the total fluid being over- or dehydrated.  
 
4.6 Pre- versus Post-Dialysis Prediction Marker 
 
The prediction (illness) marker as measured by the Bodystat Quadscan 4000 ® 
(BIA), showed a post-dialysis improved trend, as illustrated in Figure 9.  A ratio 
closer to 1.00 indicates poor cellular health or extreme fluid overload. During the 
study a total of 960 measurements were recorded, and there was only one 
incident when a value of 1 was recorded, on which day the patient’s serum 
potassium level was over 7 mmol/L (the patient admitted to eating a baked bean 
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curry the night before). The latter suggests the level of sensitivity of the 
prediction marker. 
 
 
 
Figure 9:  Pre-HD versus post-HD prediction marker of the patients shown over 
days. The post-HD prediction marker consistently improved post dialysis. 
 
4.7 Summary 
 
There was a statistically and clinically significant difference between the 
excess fluid measured per BIA and the staff estimate. This difference was 
more pronounced in patients with a body fat percentage ≥ 30 % and a BMI > 
28 kg/m2 compared to their leaner counterparts. Subjects with a body fat  ≥ 35 
% and a BMI ≥ 28 kg/m2, had a negative 3rd water space versus those with 
lower BF and BMI’s (p=0.000*). The pre-HD versus post-HD prediction marker 
of the patients over days, showed a consistently improved post-HD prediction 
marker trend. 
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Chapter 5: Discussion 
 
 
5.1 Introduction 
Fluid management is central to the management of end stage renal disease 
(ESRD). Persistent fluid overload damages the cardiovascular system, and 
leads to hypertension and left ventricular hypertrophy, congestive heart 
failure, pulmonary oedema, peripheral oedema and other adverse 
cardiovascular consequences (Moissl et al., 2013; Tsai et al., 2014).  Mortality 
risk increases with a pre-dialysis fluid overload of 2.5 litres (Moissl et al., 
2013).  Conversely, dehydration, excessive fluid removal or ultrafiltration, may 
result in intradialytic symptoms of hypotension such as acute ischaemic 
events with recurrent episodes, potentially causing functional impairment and 
organ damage (Vasko et al., 2013).  Controlling fluid status in an optimal 
range is crucial to improve cardiovascular tolerance, quality of life and survival 
of haemodialysis (HD) patients (Moissl et al., 2013). 
 
The use of bioelectrical impedance analysis (BIA) in clinical practice for the 
management of HD patients on maintenance HD is becoming increasingly 
more prevalent, and the benefits thereof have been demonstrated in recently 
published prospective randomized controlled studies (Onofriescu et al., 2014; 
Hur et al., 2013).  The implementation of BIA in clinical practice does have 
cost implications (cost of the machine and disposable tabs), so it was 
important to evaluate whether there was a clinical benefit in the South African 
context. 
 
5.2 Significant Findings 
 
5.2.1 Staff Estimated versus the BIA Measurement of Excess Fluid to be 
removed 
 
In this study, there was a significant difference (1.29 L) between the excess 
fluid measured per BIA versus the HD staff estimate.  This difference was 
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more pronounced in patients with a body fat (BF) percentage of ≥ 30 % and a 
BMI > 28 kg/m2 versus their leaner counterparts. It is suggested in future 
studies, more focus be placed on the difference of these two groups. 
 
5.2.2 Intracellular Fluid 
 
Of concern, was that all the patients irrespective of whether they were 
overhydrated or dehydrated, had an intracellular fluid % below the normal 
range.  We postulate that this patient group has an excessive sodium intake, 
resulting in fluid shifts from the intra- to the extracellular space.  Sodium levels 
not only physiologically drive thirst, but draw intracellular fluid into the 
extracellular space, and when that is saturated, results in an increase in third 
water space, which ultimately clinically presents as oedema (Charra, 2007; 
Tomson, 2001).  Persistent excess fluid in the third water space has been 
associated with progressive organ damage (including the brain) in individuals 
with ESRD (Kong et al., 2014; Zhang et al., 2015).  A sub-group of the 
patients consistently gained up to 4 litres fluid between dialysis sessions, 
which suggests both the sodium and fluid intake were not being optimally 
managed.  
 
Sodium has been found to directly increase oxidative stress, and has been 
associated with the secretion of endogenous ouabain-like substances, for 
example marinobufagenin, and endogenous ouabain.  The latter compounds 
inhibit sodium/ potassium ATPase, and may result in myocardial cell atrophy 
in vitro.  In HD patients, the concentration of endogenous ouabain has been 
found to correlate with left ventricular mass, independent of arterial pressure 
(Levin et al., 2010). 
 
In a recently published Cochrane review, it was reported that salt/ sodium 
reduction in persons with chronic kidney disease (CKD) considerably 
decreased blood pressure, and consistently decreased proteinuria. Hence, 
further under pinning the need to address excessive sodium intake in the HD 
population (McMahon et al., 2015). 
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There is a dire need for further research to be conducted in the South African, 
especially the KwaZulu-Natal HD units to establish whether the HD patients’ 
on maintenance HD, sodium and fluid intake are adequately controlled.  If 
compliance is found to be poor, then to evaluate what steps and tools can be 
implemented to achieve optimal fluid and sodium intake between dialysis 
sessions. 
 
5.2.3 Prediction Marker: Pre- versus Post-Dialysis 
 
The prediction (illness) marker as measured by the Bodystat Quadscan 4000 
® (BIA), showed a post-dialysis improved trend, as illustrated in Figure 7.  A 
ratio closer to 1.00 is indicative of poor cellular health or extreme fluid 
overload. This may prove to be a useful tool for both HD staff and patients, in 
long-term monitoring of each patient’s progress. Further studies of a longer 
duration, may elucidate over time a more significant trend, than was found in 
this study. 
 
5.2.4 Phase Angle 
 
The median phase angle of higher body fat and BMI patients were 
consistently higher compared with those of the leaner patients, suggesting a 
healthier cell mass in the group with a higher body fat and BMI. This may be 
an important piece of the puzzle that has eluded scientists for over 30 years, 
namely, the reason the HD patients with a higher body fat and BMI have a 
better survival than their leaner counterparts. 
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5.2.5 Survival Benefit of a Higher Body Fat and BMI in Dialysis Patients 
 
The reason for a survival benefit of a higher body fat % and BMI in HD 
patients has eluded scientists for the past 30 years.  Patients with a body fat 
percentage ≥30 % and a BMI ≥28 kg/m2, had a negative 3rd water space 
when compared to those with lower BF % and BMI.  We postulate that this is 
an important factor in improving this sub-groups better survival amongst HD 
patients, and that it is due to greater perspiration, and consequent higher 
water and sodium losses in this group versus their leaner counterparts. 
 
5.3 Study Limitations 
 
The population size of this study was a limitation, however, it was addressed 
through conducting consecutive repeated measures over time. The duration of 
this study, was probably not sufficient to demonstrate a significant difference in 
the pre- and post-HD prediction marker. Future studies of at least 2 years may 
be more effective in determining the level of significance. 
  
47 | P a g e  
 
Chapter 6: Conclusion and Recommendations 
 
6.1 Conclusion 
 
The aim of the study was to compare the excess fluid volume to be removed in 
haemodialysis patients as estimated by the haemodialysis (HD) unit staff and the 
volume measured by a multiple frequency bioelectrical impedance analysis (BIA) 
machine.  The outcome of which, would be used to inform future clinical practice 
for HD patients. 
 
In this study it was hypothesized that the excess fluid estimated by the HD staff 
versus the amount determined by a multiple frequency BIA machine, the 
Bodystat Quadscan 4000® would differ.  It was predicted that the BIA values are 
better indicators. In this study, there was a significant difference when comparing 
the excess fluid estimation by staff and the BIA method, even when volumes 
over different days of measurements were combined. In clinical practice, the 
difference between the excess fluid measured per BIA and the HD staff estimate 
(1.29 L difference) is profound. This difference was however, more profound in 
patients with a body fat percentage ≥ 30 % and a BMI > 28 kg/m2 when 
compared to their leaner counterparts. Also, within each of these groups, there is 
a significant difference between the staff estimation and the BIA measurements. 
 
Multiple frequency BIA is an invaluable tool for guiding both HD staff and 
patients towards an optimal fluid status in HD patients, as both extracellular and 
3rd water space can be accurately measured and monitored. Patient compliance 
in the management of end stage renal disease (ESRD) on HD is not only critical 
to their long-term survival, but may also impact on their quality of life, through 
limiting or preventing irreversible brain damage which is associated with 
cognitive impairment. It would also be concomitantly useful in monitoring HD 
patients’ nutritional status, in terms of lean body mass and fat weight. 
 
The findings (negative 3rd water space in patients with a body fat percentage 
≥30% and a body mass index (BMI) ≥28 kg/m2 and positive 3rd water space in 
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their leaner counterparts) of this study suggest that there is a potential benefit to 
a higher body fat and BMI in ESRD patients on HD, versus the conventional 
perception of a healthy BMI and body fat, namely a BMI between 19 and 25 
kg/m2, and body fat percentage between 15 and 20%. It is of utmost importance, 
that further studies in a larger population with ESRD on HD be conducted, to 
confirm this finding.  If confirmed, it may be pivotal in changing the dietary 
management of ESRD patients on HD. It is possible that current practice of 
aiming for a “healthy” body fat and BMI, maybe deleterious and is possibly 
negatively impacting on this patient populations risk for mortality, and long-term 
survival. 
 
6.2 Recommendations 
 
Further studies are necessary to evaluate South African ESRD patients on HD 
compliance in terms of salt/ sodium and fluid intake, and the modulation thereof, 
to achieve an improved long-term survival. 
 
Both national and international further investigations on the difference in 3rd 
water space between ESRD patients on HD with a higher BMI and body fat 
versus their leaner counterparts are required to further validate the findings of 
this study. If confirmed, the current dietary management of this patient 
population needs to be reviewed. 
 
A longitudinal study in a larger ESRD patient population on HD, would be useful 
in evaluating whether the usefulness prediction marker in this patient population. 
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Chapter 8: Addenda 
 
8.1  Addendum 1: Procedure for Subject Consent Counselling, 
and Data Collection 
 
 
 
 
1. Upon commencement of the study, the study objectives & written consent 
forms shall be discussed with the subject. If the subject agrees to participate in 
the study, he or she shall sign the written consent form. 
 
2. On each day of data collection, the subject shall be reminded of his/ her right 
to withdraw from the study, at any given time during the three month period of 
data collection. 
 
3. The procedure of conducting the BIA shall be explained to the subject, before 
the procedure is commenced. 
 
4. The subject shall be weighed by the nursing sister (standard daily procedure); 
refer to addendum 3. Upon the commencement of data collection, the 
subject’s height shall also be measured (refer to addendum 2). The weight shall 
be measured on an electronic scale, which shall be calibrated at the onset of 
the study, and weekly thereafter.  
 
5. The subject’s blood pressure shall be measured and recorded (standard daily 
procedure), by the nurse. 
 
6. The subject’s shall lie flat on the bed, and the HD canula shall be connected to 
the dialysis machine. 
 
7. The HD staff member shall calculate the amount of fluid to be removed during 
dialysis; that is, current body weight minus previous post dialysis (dry) weight. 
Not more than 1 litre fluid per hour shall be removed (standard daily 
procedure/ protocol). The amount of fluid to be removed shall be recorded. 
 
8. BIA measurement procedure: 
8.1 The procedure of the BIA measurement shall be explained to the subject. 
8.2  A Bodystat tab shall be attached to the subject’s right wrist and right ankle. 
8.3 The connectors (positive and negative) of the Bodystat machine shall be 
connected to the tabs attached the subject. 
8.4 The machine shall be switched on and the readings recorded. 
8.5  Once the measurements have been recorded; the results shall be explained to 
the subject. 
Procedure for Subject Consent Counselling 
and Conducting of BIA Measurements 
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8.6 The procedure shall be repeated, 15 minutes after the HD has been 
completed. 
 
9.  During the dialysis, the standard clinical practice shall be conducted, namely: 
9.1 constant measuring of the subject’s blood pressure 
9.2 the HD machine shall be checked if any alarms are triggered 
9.3 the subject shall be monitored per standard clinical observation procedure 
59 | P a g e  
 
8.2 Addendum 2: Procedure for the Measurement of Standing 
Height 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frankfort 
Horizontal Plane: 
The head is in the 
Frankfort plane 
when the 
horizontal line 
from the ear 
canal to the lower 
border of the 
orbit of the eye 
is parallel to the 
floor and 
perpendicular to 
the vertical 
backboard. 
PROCEDURE FOR MEASURING STANDING HEIGHT POSITION  
 
The Subject should: 
1) Remove his/ her shoes. 
2) Remove his/ her hat or cap or obstructing hair piece.  
3) Have his/ her head, shoulder blades, buttocks, and heels touching 
measurement surface.  
4) Have his/ her legs straight. 
5) Have feet flat. 
6) Have his/ her heels together. 
7) Have his/ her feet pointed outward. 
8) Be requested to inhale; take the measurement before he/ she exhales. 
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8.3 Addendum 3: Procedure for the Measurement of Body  
Weight 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PROCEDURE FOR MEASURING BODY WEIGHT 
 
Step 1: After the examiner shall explain the procedure to the subject. 
 
Step 2: The examiner will request that the subject: 
 
1) Void his/ her bladder. 
 
 
2)  Remove his/ her shoes. 
 
 
3) Remove any additional heavy clothing (e.g. jacket/ 
jersey/ sweater), and shall only wear light in-door 
clothing. 
 
4) Remove any items in his/ her pockets e.g. wallet or 
cellphone. 
 
5) Stand in the center of the scale platform facing the scale 
reading screen. 
 
6) Hands at his/ her sides. 
 
7) Look straight ahead.  
 
8) Weight shall be measured to the nearest 0.1kg.  
 
9) Weight measurements shall be repeated twice and the 
average of the two measurements shall be recorded.  
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8.4 Addendum 4: Calibration of Equipment 
 
 
1. Calibration of Digital scale 
1.1 A digital electronic scale with a 250kg capacity and a platform size of 305 mm 
x 305 mm to accommodate subjects with large feet shall be used. 
1.2 Weight shall be measured to the nearest 0.1kg.  
1.3 The scale shall be placed on a firm and flat surface, and calibrated with a one, 
two and five kilogram weight on a weekly basis for the duration of the study.  
 
2. Calibration Bodystat Quadscan 4000 
 
A separate BODYSTAT calibrator is supplied with each QuadScan 4000 unit 
to enable the operator to independently verify that the unit remains in 
calibration at all times. This shall be done on a monthly basis. However, this is 
only an independent check and an operator will not be able to physically re-
calibrate the unit. It is also recommended that the operator use their own body 
as another independent check. This should be performed on a subject whose 
body composition does not fluctuate greatly and remains fairly constant. 
 
2.1 PROCEDURE 
2.1.1 Attach one pair of red and black leads to any one terminal of the 
calibration unit. 
2.1.2 Then attach the other pair of red and black leads to the other terminal of 
the calibration unit. 
2.1.3 Switch the unit ON and enter any subject data or accept the default 
displays on the LCD screen. 
2.1.4 Provided that the leads have been correctly attached to the calibrator and 
after "MEASURING" is displayed, scroll through the results until the 
Impedance values are reached.  
2.1.5 The results at all four impedance values should reflect readings of 
between 496 to 503, approximately a 0.5% variance on either side of the 
high precision 500 ohm resistor in the BODYSTAT calibrator. 
2.1.6 If the readings are outside of this range, the following should be 
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checked: 
■ Are the leads correctly attached as per the procedure above? 
■ If the results are still incorrect, first replace ALL six batteries with 
new Duracell or Procell batteries (see BATTERY REPLACEMENT 
section of the User’s Guide). 
■ If the unit remains outside of the calibration range, contact 
BODYSTAT LTD or your dealer. 
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8.5 Addendum 5: Data Sheet – Allocation of Research Codes to 
     Subjects 
 
Allocation of Data Collection Codes 
Code Subjects Name 
Subjects Out-
patient Number 
X1     
X2     
X3     
X4     
X5     
X6     
X7     
X8     
X9     
X10     
X11     
X12     
X13     
X14     
X15     
X16     
X17     
X18     
X19     
X20     
X21     
X22     
X23     
X24     
X25     
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8.6 Addendum 6: Subjects Demographics 
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8.7 Addendum 7: Daily & Monthly Data Collection Spreadsheets 
 
Addendum 7: DAILY/WEEKLY/ MONTHLY DATA SHEET
Patient  Code: X Age Sex
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Date:
HD Unit staff code
Bodystat Machine Code
Last Post Dialysis Wt
Predialysis Wt
Post Dialysis Wt
Fluid to be removed
No. of hrs on HD
Fat %
Fat % N Range - min
Fat % N Range - max
Fat wt in kg
Fat wt in kg range -min
Fat wt in kg range -max
Lean %
Lean % N Range - min
Lean % N Range - max
Lean wt (kg)
Lean wt range (kg) - min
Lean wt range (kg) - max
Total B wt (kg)
Total B wt N range - min
Total B wt N range - max
Dry Lean wt (kg)
TBW - Total Fluid (Pre) %
TBW Total Fluid N range % - min
TBW Total Fluid N range % - max
TBW Total Fluid (Pre) L
TBW Total Fluid N range L -min
TBW Total Fluid N range L -max
ECW %
Extracellular Fluid % N 
ECW -Extracellular Fluid (Pre) L
ICW -Intracellular Fluid (Pre) %
ICW - Intracellular Fluid (Pre) % N
Intracellular Fluid (Pre) L
Body Cell Mass (kg)
Third Space (Fluid Overload Vol) L
Prediction/ Illness Marker (Pre)
BMR (Kcal)
BMR/ body wt (Kcal/ kg)
Est Average Req (Kcal)
BMI
BMI Range -min
BMI Range - max
Phase Angle 50K
BIA Machine code
TBW - Total Fluid (Post) %
TBW Total Fluid N range % - min
TBW Total Fluid N range % - max
TBW Total Fluid (Post) L
TBW Total Fluid N range L - min
TBW Total Fluid N range L - max
ECW - Extracellular Fluid (Post) %
Extracellular Fluid % N 
ECW -Extracellular Fluid (Post) L
ICW -Intracellular Fluid (Post) %
ICW - Intracellular Fluid (Post) % N
Intracellular Fluid (Post) L
Body Cell Mass (kg)
Third Space (Fluid Overload 
Volume) L
Prediction/ Illness Marker (Post)
Phase Angle 50K
BP (Pre)
BP (Post)
Serum Albumin
Height:
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8.8 Addendum 8: Subject Consent Forms – English and Zulu 
Version and UKZN and DOH Ethics Approval to Conduct the Study 
 
 
 
 
 
TITLE OF THE RESEARCH PROJECT:  To Determine the Difference in Extracellular Fluid 
(Excess) to be removed in Chronic Haemodialysis 
Patients, estimated by the Haemodialysis Unit Staff 
versus the Multiple Frequency BIA Measurement.  
 
ETHICS REFERENCE NUMBER:  BE041/14 
 
INVESTIGATORS:  Jane Downs (Chief Dietitian and HOD Dietetics Dept, King 
Edward VIII Hospital, Durban, KZN). 
 
ADDRESS: c/o Dietetics Dept, King Edward VIII Hospital, Private Bax X01, Congella, 
Durban, 4013 
 
CONTACT NUMBER:  Jane Downs: 031-3603293 
 
 
 
I would like to invite you to take part in this research project, which is part of my 
Dietetics Masters studies (MSc). 
 
Please take some time to read the information presented here, which will explain the 
details 
  of this project.  Please ask the researcher any questions about any part of this project 
that you do not fully understand.  It is very important that you are fully satisfied that 
you clearly understand what this research entails and how you will be involved.  
Also, your participation is entirely voluntary and you are free to decline to 
CONSENT FORM AND INFORMATION REGARDING THE 
RESEARCH PROJECT AT YOUR HOSPITAL 
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participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do initially 
agree to participate. 
 
This study has been approved by the Ethics BREC Committee (Medical School) of 
the University of KwaZulu-Natal and will be conducted according to the ethical 
guidelines and principles of the international Declaration of Helsinki, South African 
Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
 
What is this research study all about? 
The study will be conducted at the King Edward VIII Hospital Haemodialysis unit. A 
non-invasive bioelectrical impedance assessment (measurement) shall be 
performed on each dialysis patient that agrees to participate in the study, before 
and after each dialysis treatment. A special machine (Quadscan) will be used in this 
research project, in which a small undetectable current will pass through your body 
from your right hand to your right foot.  
This machine measures various measurements, namely, your fluid inside and outside 
the cells in your body (intra & extracellular fluid). It accurately measures of your 
excess fluid outside your body’s cells (extracellular) fluid (which needs to be 
removed during dialysis). This will be compared to what the Haemodialysis unit staff 
estimate in terms of how much fluid should be removed. The bioelectrical 
impedance assessment measurement will be used to guide the HD unit staff, on how 
much fluid needs to remove during your dialysis.   
All information collected will be treated as confidential.  
 
Why have you been invited to participate? 
This study is being conducted exclusively at King Edward VIII hospital and only the 
HD patients in the chronic program will be invited to participate.  
 
What will your responsibilities be? 
The collection of the data involves: 
1. You will be weighed pre- and post-dialysis, as per your usual treatment 
program, by the HD nursing staff. 
2. While the Haemodialysis staff prepare the haemodialysis machine for your 
dialysis, the dietitian/ researcher, shall attach 2 tabs on your right hand and 2 
on your right foot, and connect the Quadscan to the tabs. 
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3. The machine will give various readings. One of which will be your extracellular 
fluid, which will be used to guide the haemodialysis staff on how much excess 
fluid outside the cells (extracellular) to remove. 
4. At the end of your dialysis session the dietitian/ researcher will repeat the BIA 
measurement. This is to assess the change in the volume of your excess fluid 
outside the cells (extracellular), and to assess whether your illness marker has 
improved. The illness marker is an indirect measure that will help assess how 
healthy the cells in your body are. If your body fluid management improves 
with time, this marker will also improve with time. 
5. No special blood tests are required in this study. Only the tests that are routinely 
carried out will be used as data for the study. 
6. The tests will be repeated on each of your haemodialysis treatments (2 times 
per week) over a 3 month period. 
   
Will you benefit from taking part in this research? 
Yes, the research might benefit you, as well as, future patients that need 
haemodialysis. The main goal of this study is to assess whether the estimated amount 
of fluid to be removed, as estimated by haemodialysis staff is accurate. If not, to 
assess whether there is a need to implement the Quadscan measurements as 
standard practice, to improve haemodialysis patients’ fluid management. Excess 
extracellular fluid (fluid outside the cells in the body) has been shown to cause heart 
failure and increase the risk or aggravate high blood pressure, amongst other 
possible side-effects.  
 
Furthermore, the illness marker will be a helpful tool to show you how your body is 
responding to the haemodialysis treatment. If it significantly improves in most of the 
patients in this study, this will provide evidence to motivate for this assessment to be 
used not only in the King Edward Hospital VIII Haemodialysis unit, but in all the 
haemodialysis units throughout South Africa. 
 
Are there in risks involved in your taking part in this research? 
There are no risks associated with taking part in the study. The usual monitoring and 
clinical practice measures used for your haemodialysis treatment shall be 
conducted. This assessment has been scientifically validated as a tool, and is used 
as in standard practice in haemodialysis treatment centres in other countries, for 
example in the United Kingdom. 
 
If you do not agree to take part, what alternatives do you have? 
Participation in this study is entirely voluntary. Standard care will not be withheld in 
the event of you deciding not to participate. You are also free to withdraw at any 
time, even if you initially agreed to participate in the study, but later decide not to. 
Who will have access to the information collected at your hospital? 
All information collected in this research project, will be treated as confidential, and 
will be stored in a safe and secure location.  When the data (information collected) 
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is reported, the hospital and patients/subjects will be referred to in coded format.  
The researchers are the only people who will have access to the information 
collected. If the data (information collected) is used in a publication or thesis, 
patient identification will be kept anonymous. 
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
As this study does not involve any invasive procedures or drug testing, it is highly 
unlikely that any injury will occur as a result of taking part in this study.  
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study and there will be no costs involved 
for you, if you do take part. The measurements shall be conducted on your usual 
treatment days and times. 
 
Is there anything else that you should know or do? 
Should you have any further queries or encounter any problems regarding the study, 
you can contact Ms Jane Downs on telephone number 031-3603293. 
 
If you have any concerns or complaints, that have not been adequately addressed 
by the researcher, you can contact the UKZN BIOMEDICAL RESEARCH ETHICS COMMITTEE 
(BREC) at telephone number: 031 2604769. The full BREC contact details are: 
 
University of KwaZulu-Natal  
Research Office 
Biomedical Research Ethics Administration 
Westville Campus, Govan Mbheki Building, 
Private Bag x54001, Durban, 4000 
Tel: 27 31 2604769; Fax:27 31 2604609 
E-mail: BREC@ukzn.ac.za 
Website: http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-
Ethics,aspx 
  
You will receive a copy of this information and consent form for your own records. 
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INFORMED CONSENT FOR RESEARCH AT YOUR HOSPITAL 
 
Declaration by Participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research 
study titled “To Determine the Difference in excess Fluid to be removed in Chronic 
Haemodialysis Patients, estimated by the Haemodialysis Unit Staff versus the Multiple 
Frequency BIA Measurement.” 
 
I declare that: 
 I have read or had read to me this information and consent form and it is 
written in a language in which I am fluent and am comfortable with. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to withdraw from the study at any time and will not be 
penalised or prejudiced in any way as a result. 
 I may be asked to withdraw from the study before it has finished, if the 
researcher feels it is in my best interests, or if I do not follow the study plan, 
as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2014. 
 
 
......................................................................   ...................................................................  
Signature Signature of witness 
 
......................................................................   ...................................................................  
Designation Name of witness 
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Declaration by Investigator 
 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to 
answer them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2014. 
 
 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
 
 
......................................................................   ...................................................................  
Name of investigator Name of witness 
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Zulu Version of the Patient Consent Form: 
 
 
 
ISIHLOKO SOCWANINGO:  Ukuveza umehluko emanzini angaphandle kwamaseli 
(excessr fluid) (angaphezu kwesilinganiso) okumele 
asuswe ezigulini ezihlala nokuphila kwesifo sezinso 
njengokokuhlambekisela kwabasebenzi basophikweni 
lwe-Haemodialysis lapho kuqhathaniswa ne-Multiple 
Frequency BIA Measurement. 
 
IKHODI YOPHIKO LWEMIGOMO YOKUZIPHATHA: BE041/14 
 
ABACWANINGI: Jane Downs (Oyinhloko yama-dietician aphinde abe ngumphathi 
ephikweni lwe-Dietetics esibhedlela iKing Edward VIII, eThekwini, KwaZulu;Natal).  
 
IKHELI: c/o Dietetics Dept, King Edward VIII Hospital, Private Bag XO1, Congella, 
Durban, 4013 
 
INOMBOLO YOCINGO: Jane Downs: 031-360 3293 
 
 
Ngithanda ukukumema ukuba ube yingxenye yalolu cwaningo, okuyingxenya 
yezifundo zami za-Masters kwi-Dietetics (Msc). 
 
Ngicela ukuba uthathe isikhathi ukuba ufunde lokhu okubhalwe lapha, 
okuzokucacisela ngemininingwane yalolu cwaningo. Ngicela ukuba umhlohle 
imibuzo umcwaningi nangonoma yini ongayiqondi ngalolu cwaningo. Kubalulekile 
ukuba waneliseke futhi ucaceliseleke kahle ukuthi lolu cwaningo lumayelana nani 
kanye nokwazi ukuthi luzodingani. 
 
Okunye futhi okumele ukuqonde ukuthi ukuba yingxenye yalolu cwaningo 
akunampoqo kanti futhi ukhululekile ukuba wenqabe ukuba yingxenye yalo. Uma 
wenqaba ukuba yingxenye yalo ucwaningo, Angeke uze ubukeke njengomuntu 
omubi. Uvumelekile futhi ukuba ungahoxa nanoma yinini ekubeni yingxenye yalolu 
cwaningo yize noma kade wawuvumile ekuqaleni. 
Lolu cwaningo lugunyazwe yi-Ethics BREC Committee yase-KwaZulu-Natal University 
Medical School kantu luzokwenziwa kulandelwa imigomo kanye nemithetho 
yokuziphatha ebekwe yi-International Declaration of Helsinki, yi-South African 
Guidelines for Good Clinical Practice kanye ne-Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
Lumayelana nani lolu cwaningo? 
Lolu cwaningo luzokwenziwa eSibhedlela iKing Edward VIII ophikweni lwe-
Haemodialysis. Kuzosetshenziswa isikali sikagesi esingenabungozi kuzo zonke iziguli 
ezisohlelweni lokukhuculula izinso ezizovuma ukuba yingxenye yalolu cwaningo, 
ngaphambi kanye nangemuva kokuba sezikhuculiwe izinso. Uhlobo oluthile lomshini 
olwaziwa nge-Quadscan luzokusetshenziswa kulolu cwaningo lapho kuzodedelwa 
 
IFOMU LEMVUME NOLWAZI MAYELANA NOCWANINGO ESIBHEDLELA SAKHO 
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umbani (current) omncanyana ukuba udlule emzimbeni wakho kusukela esandleni 
sokudla kuye onyaweni lwakho losokudla.  
 
Lo mshini uzokunikeza izikalo eziningi okubalwa kuzo, amanzi angaphakathi okanye 
angaphandle kwamaseli (cells) asemzimbeni wakho. Lo mshini ukala ncimishi 
amanzi evile angaphandle kwamaseli omzimba wakho adinga ukususwa lapho 
kukhucululwa izinso. Lokhu kuzobe sekuqhathaniswa nalokho abasebenzi base-
Haemodylasis abakuhlambekisayo ekuthenini mangakanani amanzi okumele 
asuswe. Lokhu kuhlola kuzokusiza abasebenzi basophikweni lwe-Haemodialysis 
njengomhlahlandlela ekuthenini mangakanani amanzi opkumele asuswe lapho 
kukhucululwa izinso. 
Lonke ulwazi oluzotholakala luzothathwa njengoluyimfihlo. 
  
 Kungani umenywe ukuba yingxenye yalolu cwaningo? 
Lolu cwaningo luzokwenzenziwa eSibedlela iKing Edward VIII kuphela kanti yiziguli 
kuphela ezinesifo sezinso ezingamahlalakhona ezizokuba yingxenye yalolu 
cwaningo. 
 
Kuzokuba yiliphi iqhaza lakho? 
Ukuqoqwa kolwazi kuzodinga lokhu: 
1. Njengnjwayelo, onesi abangabasebenzi basophikweni lwe-Haemodialysis 
bazokukala iziguli ngaphambi nangemuva kokukhucululwa izinso. 
2. Ngesikhathi abasesebenzi bohlelo lwe-Haemodialysis belungisa umshini 
wokukhuculula izinso, umcwaningi oyi-dietician uzokunamathisela 
izigqebhezana ezimbili esandleni sakho sokudla kanye nasonyaweni lakho 
lokudla bese exhuma umshini i-Quadiscan kuzo izigqebhezana. 
3. Umshini lo uzokuveza imibhalo eyahlukene, enye yawo okungowamanzi 
angaphandle kwamaseli ezokusetshenziswa ukwazisa abasebenzi bohlelo 
lwe-Haemodylasis ukuthi lingakanani inani lwamanzi eleqile olungaphandle 
kwamaseli okumele lususwe. 
4. Ukupheleni kohlelo lokukhucululwa izinso, umcwaningi oyi-dietician 
uzokuphinda futhi athathe izikalo ngohlelo lwe-BIA. Lokhu uzokwenza ukuhlola 
amazi eqile angaphandle kwamaseli kanye futhi nokuhlola ukuthi isikali sakho 
sokugula sesigcono (illness marker) yini. Lokhu kuwukuhlola ngendlela 
ecashile isimo sempilo samaseli asemzimbeni wakho. Uma kuwukuthi 
ukuphatheka kwamanzi asemzimbeni wakho kuba ngcono ngokuhamba 
kwesikhathi, lokho kusho ukuthi lesi sikali naso sizokuba ngcono 
ngokuqhubeka kwesikhathi. 
5. Akukho ukuhlolwa kwegazi okukhethekile okuzokwenziwa kulolu cwaningo. 
Imininingwane yokuhlolwa okujwayelekile ezokusetshenziswa kulolu 
cwaningo. 
6. Ukuhlolwa kuzokuphindwa njalo uma uze u ukuzokhucululwa izinso (kabili 
ngesonto) kuze kuphele izinyanga ezintathu. 
 
Kukhona ozokuzuza ngokuba yingxenye yalolu cwaningo? 
Yebo, lolu cwaningo lungakuzuzisa, kanti futhi neziguli zangomuso ezidinga 
ukukhucululwa izinso, nazo zingahlomula. Injongo enkulu  yalolu cwaningo ukuhlola 
ukuthi inani lamanzi elihlambikiselwe okumele lisuswe, njengokuhlambiselwa 
ngabasenzi bohlelo lwe-haemodialyis, liyilo yini ncimishi. Uma kungenjalo, sikhona 
yini isidingo sokusebenzisa izikalo ze-Quadiscan njengomkhuba ukuphucula 
ukuphatheka kwamanzi emzimbeni weziguli lapho kukhucululwa izinso. Kweminye 
yemithelela emibi ebangwa ngamanzi evile angaphandle kwamaseli (amanzi 
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angaphandle kwamaseli emzimbeni) kubalwa ukwehluleka kokusebenza 
kwenhliziyo kanye nengozi engenzeka yokwenyuka komfutho wegazi. 
 
Ngaphezu kwalokhu, isikali sokugula sizokusiza ukukhombisa ukuthi umzimba wakho 
uzwana kanjani nokulashwa kusetshenziswa uhlelo lokukhucululwa izinso. Uma 
kuwukuthi iziguli eziningi ziyasizakala kulolu cwaningo, lokhu kuzokunikeza ubufakazi 
obuzokugqugquzela lolu hlelo ukuthi lungasetshenziswa ophikweni lwe-Haemodialyis 
lwaseSibhedlela iKing Edward VIII kuphela, kodwa lusetshenziswe eNingizimu Afrika 
yonkana. 
 
Bukhona ubungozi ekubeni yingxenye yalolu cwaningo? 
Abukho ubungozi obukhona obumbandakanywa nokuba yingxenye yalolu 
cwaningo. Kuzokukalwa ngendlela eyejwayelekile lapho kuzokukhucululwa izinso. 
Lolu hlelo luhloliwe kanti lusetshenziswa mihla yonke ophikweni lwe-Haemodialysis 
kwamanye amazwe afana nelaseNgilandi. 
 
Uma ungavumi ukuba yingxenye yalolu cwaningo, yini ongayenza? 
Akusiyo neze impoqo ukuba yingxenye yalolu cwaningo. Angeke uze ubanjelwe 
igqubo uma ukhetha ukuba ungazimbandakanyi nalolu cwaningo. Uvumelekile 
futhi ukuba uhoxe nanoma yinini, yize noma wawukade uvumile ekuqaleni bese 
unquma ukungazimbandakanyi ngokuhamba kwesikhathi. 
 
Ngubani esibhedlela ozolubona ulwazi oluqoqiwe mayelana nalolu cwaningo? 
Lonke ulwazi oluqoqwe kulolu cwaningo luzokuthathwa njengemfihlo luphinde 
lugcinwe endaweni ephephile. Uma selubikwa ulwazi oluqoqwe kulolu cwaningo, 
igama lesibhedlela kanye namagama eziguli angeke kuze kubhadlazwe kodwa 
kuzobizwa ngamakhodi athile. Abacwaningi ukuphela kwabantu abazokwazi 
ukubona ulwazi oluqoqiwe. Uma lolu lwazi kwenzeka lusetshenziswa oshicililweni 
oluthile, igama lesiguli angeke lize lidalulwe. 
 
Kuzokwenzakalani uma kwenzeka ulimala ngenxa yokuba yingxenye yalolu 
cwaningo? 
Njengoba bungekho ubungozi okanye izidakamizwa ezisetshenziswayo kulolu 
cwaningo, amathuba mancane kakhulu ukuthi kukhona ukulimala ongakuthola 
ngenxa yokuba yingxenye yalolu cwaningo. 
 
Uzokukhokhelwa ngokuba yingxenye yalolu cwaningo okanye zikhona yini 
izindleko ngalolu cwaningo? 
Cha angeke uze ukhokhelwe ngokuba yingxenye yalolu cwaningo kanti futhi azikho 
izindleko ozokhokhelwa zona. Izikalo zizokwenziwa ngezinsuku kanye nangezikhathi 
ezijwayelekile owelashwa ngazo.  
 
Kukhona yini okumele ukwazi noma ukwenze? 
Uma unemibuzo okanye uhlangabezana nezinkinga eziqondene nalolu cwaningo, 
ungathintana noNksz Jane Downs kule nombolo 031 360 3293.  
 
Uma kukhona izinkinga okanye izikhalazo umcwaningi angazange akucacisele 
zona,  
ungaxhumana ne- UKZN BIOMEDICAL ETHICS COMMITTEE (BREC) kule nombolo: 031 
2604769. 
Uzokunikezwa ikhophi yalolu lwazi kanye nefomu lemvume ukuba uzigcinele wena. 
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Imininingwane ephelele yawa-BREC ithi: 
 
iNyuvesi-YaKwaZulu-Natal  
Research Office 
Biomedical Research Ethics Administration 
Westville Campus, Govan Mbheki Building, 
Private Bag x54001, Durban, 4000 
Tel: 27 31 2604769; Fax: 27 31 2604609 
E-mail: BREC@ukzn.ac.za 
Website: http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-
Ethics,aspx 
 
 
 
IMVUME YOKWENZA UCWANINGO ESIBHEDLELA SAKHO 
 
 
Isifungo ikalowo ozokuba yingxenye yalolu cwaningo 
 
Ngokusayinda ngenzansi, mina…………………………………………….ngiyavuma 
ukuba yingxenye yalolu cwaningo olusihloko sithi  Ukuveza umehluko emanzini 
angaphandle kwamaseli (extracellular fluid) (angaphezu kwesilinganiso) okumele 
asuswe ezigulini ezihlala nokuphila kwesifo sezinso njengokokuhlambekisela 
kwabasebenzi basophikweni lwe-Haemodialysis lapho kuqhathaniswa ne-Multiple 
Frequency BIA Measurement. 
 
Ngiyakufungela ukuthi: 
 Ngikufundile okanye ngifundelwe lokhu okubhalwe lapha kanye nefomu 
lemvume. Lokhu kubhalwe ngolimi engilwaziyo nengiluqondayo kahle 
kakhulu. 
 Nginikeziwe ithuba lokuphonsa imibuzo kanti nemibuzo yami iphendulekile 
ngokugculisayo. 
 Ukuba yingxenye yalolu cwaningo akusiyo impoqo kanti name angizange 
ngiphoqwe ukuba ngibe yingxenye yalolu cwaningo. 
 Ngingazikhethela ukuyeka ukuba yingxenye yocwaningo nanoma yinini 
kanti angeke ngihlawuliswe okanye ngicwaswe ngokwenza njalo. 
 Ngingacelwa ukuba ngiyeke ukuba yingxenye yalolu cwaningo ngaphambi 
kokuba luphele uma kuwukukuthi umcwaningi ubona sengathi ngizosizakala 
okanye ubona sengathi angiyilandeli imigomo yalo ucwaningo 
njengokwesivumelwano. 
 
Isayindwe e- 
(indawo)…………………………………………………………………………………..mhlaka 
(usuku)……………………….2014. 
 
……………………………………………..                               
…………………………………………………….. 
Sayinda                                                                          Ukusayinda kukafakazi 
 
……………………………………………..                                 
…………………………………………………… 
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Umsebenzi wakho                                                       Igama likafakazi 
 
Isifungo sikamcwaningi 
 
Mina 
(igama)………………………………………………………………………………………….ngiya
kufungela ukuthi: 
 Ngiyichaze yonke imidanti ebhalwe lapha uku………………………. 
 Ngibagqugquzelile abantu ukuba baphonse imibuzo kanti name ngichithe 
isikhathi esamele ukuyiphendula. 
 Nganelisekile ukuthi abantu bayiqonde kahle kakhulu imidanti yalolu 
cwaningo njengoba ibaluliwe ngasenhla. 
 Ngimusebenzisile/ angimsebenzisanga utolika. (Uma kuwukuthi umsebenzisile 
utolika, kumele asayinde lesisi fungo esingenzansi). 
Isayindwe e-(indawo)………………………………………………………..mhlaka 
(usuku)……………………….2014. 
 
 
 
………………………………………………...                             
………………………………………………… 
 
Ukusayinda komcwaningi                                                          Ukusayinda kukafakazi 
 
 
 
…………………………………………………                             
……………………………………………… 
Igama lomcwaningi                                                                       Igama likafakazi 
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